Medicenna Therapeutics to Present at Upcoming March Investor Conferences

TORONTO and HOUSTON, March 04, 2021 (GLOBE NEWSWIRE) — Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced that Dr. Fahar Merchant, President, CEO and Chairman of the Board of Medicenna, will be presenting at the H.C. Wainwright Global Life Sciences Conference and at the Oppenheimer 31st Annual Healthcare Conference, as well as participating in a live panel discussion at the Maxim 2021 Emerging Growth Virtual Conference. All three virtual investor conferences will take place in March 2021.

Details are as follows:

H.C. Wainwright Global Life Sciences Conference

Format: Pre-Recorded Presentation
Date: Available on-demand starting at 7 am ET on Tuesday, March 9, 2021        

Oppenheimer 31

st

Annual Healthcare Conference

Format: Live Presentation
Date: Wednesday, March 17
Time: 2:30 pm ET

Maxim 2021 Emerging Growth Virtual Conference

Format: Live Glioblastoma Panel Discussion and Pre-Recorded Presentation
Date: Wednesday, March 17
Time: 11:00 am ET

Webcast and replay links and further information for these events will be available on the Investor Relations section of Medicenna’s website at https://ir.medicenna.com/.

About Medicenna

Medicenna is a clinical stage immunotherapy company focused on the development of novel, highly selective versions of IL-2, IL-4 and IL-13 Superkines and first in class Empowered Superkines for the treatment of a broad range of cancers. Medicenna’s long-acting IL2 Superkine asset, MDNA11, is a next-generation IL-2 with superior CD122 binding without CD25 affinity and therefore preferentially stimulates cancer killing effector T cells and NK cells when compared to competing IL-2 programs. Medicenna’s lead IL4 Empowered Superkine, MDNA55, has completed a Phase 2b clinical trial for rGBM, the most common and uniformly fatal form of brain cancer. MDNA55 has been studied in five clinical trials involving 132 subjects, including 112 adults with rGBM. MDNA55 has obtained Fast-Track and Orphan Drug status from the FDA and FDA/EMA, respectively.

Forward-looking statement

This news release contains forward-looking statements under applicable securities laws and relate to the future operations of the Company and other statements that are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects”, “believes” and similar expressions. All statements other than statements of historical fact, included in this release, including the future plans and objectives of the Company, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company’s expectations include the risks detailed in the annual information form of the Company dated May 14, 2020 and in other filings made by the Company with the applicable securities regulators from time to time in Canada and the United States.

The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect and that study results could change over time as the study is continuing to follow up all subjects and new data are continually being received which could materially change study results. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements only as expressly required by Canadian and United States securities law.



Further Information

For further information about the Company please contact:

Elizabeth Williams, Chief Financial Officer, 416-648-5555, [email protected]   

Investor Contact

For more investor information, please contact:

Dan Ferry, Managing Director, LifeSci Advisors, 617-430-7576, [email protected] 

SRHI Inc. Business Update and Reports 2020 Annual Results

(all amounts expressed in US dollars)

TORONTO, March 04, 2021 (GLOBE NEWSWIRE) — SRHI Inc. (“SRHI” or the “Company” – formerly Sprott Resource Holdings Inc.) today announced its operating and financial results for the year ended December 31, 2020. The Company’s principal operating business is its 70% owned producing copper mine Minera Tres Valles SpA (“MTV“) in Salamanca, Chile. The Company’s financial statements and management’s discussion and analysis (“MD&A“) are available at www.srhi.ca and www.sedar.com.

  • MTV restarts operations at its open pit, Don Gabriel
  • Construction and development of its incline block caving mine at its Papomono Masivo deposit (“Papomono Masivo“) remains on schedule and on budget to be in commercial production by early 2022
  • The new chloride leaching (“Salt Leach“) process provides early indications of success

“Since the emergence of the global COVID-19 pandemic, the Company reacted quickly and decisively during a fluid and fast-moving environment,” said Terry Lyons, Interim CEO of SRHI. “The Company adjusted its business procedures and processes while ensuring the safety of its employees, contractors and host communities. Fortunately, the number of COVID-19 cases in the Company has been very limited. The Company continues its preventative, mitigating and containment measures to actively minimize the spread of COVID-19 and has restricted travel, and instructed employees to remote work wherever possible, including at corporate offices.”

“This past year was a difficult one for the Company but we have renewed optimism going forward as we look to advance the operations of MTV in a way we were unable to in 2020,” stated Michael Staresinic, President and Chief Financial Officer. “Successfully exiting the restructuring process late in the year allowed the Company and its employees to begin executing its plan to profitability. The successful construction and development of the Papomono Masivo incline block caving project will be critical to accomplishing this and is the most important part of MTV’s future success.”

“The current copper price is above our planned expectations and is welcomed,” added Mr. Staresinic. “We continue to operate well below our operating capacity due to fewer available areas to mine and this will result in temporarily high unit costs throughout 2021. Looking into 2022 and as Papomono Masivo ramps up and delivers sustained production, we expect to see these high unit costs reduce as production increases and higher grade ores are accessed. Our view on copper remains positive and we believe Chile, in terms of prospectivity and business climate, is one of the best jurisdictions in the world to build a copper business. As mentioned in our guidance press release, our focus for production this year will come from our recently restarted operations at our Don Gabriel open pit and our current inventory, together with ore expected from third-party miners as well as from ENAMI, Chile’s National Mining Enterprise.”

“This coming year will be an exciting year on many fronts – worldwide vaccine deployment with the hope of returning to normality, the construction and development of Papomono Masivo leading to a path to profitability, a robust copper price environment and the continued increase in demand for electric vehicles,” continued Mr. Staresinic. “We believe we are well positioned and invite shareholders, interested parties and potential investors to explore our website at www.srhi.ca together with our corporate presentation for more information.”

Operational Results Summary

  Three months ended Year ended
Operating information Dec. 31, 2020 Dec. 31, 2019 Dec. 31, 2020 Dec. 31, 2019
Copper (MTV Operations)        
Total ore mined (thousands of tonnes) 57   313   408     1,210  
Grade of ore mined (% Cu) 1.34 % 0.64 % 0.92   % 0.65 %
Total waste mined (thousands of tonnes) 57   1,678   910     6,196  
Ore Processed (thousands of tonnes) 100   364   574     1,433  
Cu Production (tonnes) 1,094   1,879   4,883     7,055  
Cu Production (thousands of pounds) 2,411   4,142   10,765     15,555  
Change in inventory ($000s) $ 677   $ 1,320   $ (3,744 )   $ 12,129  
Cash cost of copper produced 1 (USD per pound) $ 2.80   $ 2.82   $ 2.71     $ 2.66  
Realized copper price 1 (USD per pound) $ 3.03   $ 2.68   $ 2.58     $ 2.66  


1
  Refer to Non-IFRS Performance Measures

Financial Results Summary

  Three months ended Year ended
Financial information (in thousands) Dec. 31, 2020


  Dec. 31, 2019   Dec. 31, 2020


  Dec. 31, 2019  
Revenue $ 6,003     $ 9,352     $ 23,703     $ 35,688    
Gross loss $ (1,204 )   $ (4,454 )   $ (10,750 )   $ (13,376 )  
Net loss from continuing operations $ (6,920 )   $ (21,398 )   $ (28,087 )   $ (45,347 )  
Net loss from discontinued operations $     $ (4,427 )   $ (2,241 )   $ (6,855 )  
Net loss for the period $ (6,920 )   $ (25,825 )   $ (30,328 )   $ (52,202 )  
         
Adjusted EBITDA from continuing operations 1 $ (2,661 )   $ (355 )   $ (6,480 )   $ (5,038 )  
Loss on portfolio investments $ (380 )   $ (1,358 )   $ (1,674 )   $ (9,936 )  
Impairment of non-current assets $     $ (13,666 )   $ (7,628 )   $ (13,666 )  
Write-down of inventory, net of reversals $ (856 )   $ (2,324 )   $ (4,297 )   $ (4,383 )  
Gain (loss) on modification of debt $ (240 )   $     $ 3,247     $    
Cash used in operating activities before working capital changes $ (2,416 )   $ (19,354 )   $ (6,828 )   $ (24,902 )  


1

Refer to Non-IFRS Performance Measures

Business Update

Restart of Operations at Don Gabriel

In mid-December 2020, the open pit operations at Don Gabriel restarted. This will be the primary source of ore for the operation during 2021 with approximately 600,000 tonnes of ore expected to be processed.

Construction and Development of Papomono Masivo

On November 8, 2018, the Company announced its results from a series of technical studies (the “Technical Studies”) on MTV that was consolidated into a NI 43-101 technical report (the “Technical Report”) that was filed on December 14, 2018. The Technical Studies were authored by Amec Foster Wheeler, a Wood company (“Wood”) along with contributions from independent consulting firms that included:

  • Mineral resource and mineral reserve estimates for the Papomono deposits; and,
  • A Preliminary Feasibility Study (“PFS”) for the underground exploitation of the Papomono Masivo mine zone.

The Technical Studies concluded that a total capital cost of US$21 million would be required (the “PEA Case”) to ramp-up operations to approximately 18,000 tonnes per annum of copper cathodes within 24 months together with an additional $31 million of sustaining/development capital costs. Upfront capital costs of $7.8 million and sustaining/development capital costs of $6.7 million were identified for the Papomono Masivo project in the PEA Case.

In early 2020, the Company completed additional detailed engineering work to optimize certain aspects of the construction and development of the Papomono Masivo deposit. This additional work was the basis for the negotiation of the contract with Desarrollos Mineros Aura SpA that has a value of $11.4 million based on the most recent specifications obtained from this detailed engineering study. The majority of this $11.4 million is considered upfront capital costs compared to the $7.8 million identified in the Technical Studies. Although some of this amount has been incurred, the majority of these capital expenditures will be completed during 2021.

Under the base case mine plan, the mineral reserve estimate for Papomono Masivo is 3,067kt of proven and probable mineral reserves (at a copper grade of 1.51%).

Salt Leach Project

The implementation of the Salt Leach involves adding rock salt (NaCl) in the agglomeration stage of the crushing plant allowing the mixed sulphide and oxide material to cure on the heap for at least 30 days before commencing leaching. The accelerated oxidation of sulphide material by the addition of salt to the heaps is expected to improve copper recoveries by approximately 5% to 10%, reduce acid consumption by up to 40%, and decrease the leach time by approximately 40%. The Salt Leach project development and construction commenced in mid-2018 and was commissioned in July, 2019 ahead of schedule with no interruption to the solvent-extraction and electrowinning processing plant operations. MTV began increasing the addition of salt in September 2020 and reached design parameters in early 2021.

The ore from the restart of Don Gabriel in late December 2020 was processed using the Salt Leach and early results are encouraging.

Exploration

MTV has a significant strategic land package of over 46,000 hectares in a good neighborhood that is expected to be explored in the coming years. These property holdings are in the well-known copper producing Coquimbo region which has Antofogasta Minerals’ Los Pelambres mine located approximately 50 kilometers to the east of MTV. With more than 100 copper outcrop occurrences and 70 artisanal mining sites with geological characteristics similar to that of the Papomono and Don Gabriel orebodies, together with near-term infill drilling opportunities, the Company believes there is significant exploration potential.

COVID-19

The COVID-19 introduction to our global society over the past year is generational with different reactions observed from country to country. COVID-19 implications remain unknown and continue to move at a pace unmatched in recent history with a second wave still impacting many countries worldwide. The world’s financial marketplace has seen significant volatility with the copper price sharing similar dynamic movements. What once were significant losses across the world’s financial marketplace have turned to near full recoveries in many cases.

The situation is dynamic with various cities and countries around the world responding in different ways to address the outbreak. Countries have closed borders, travel has plummeted and some health care systems have been overrun. However, there are a sizable number of countries that have made tremendous progress in containing the spread of COVID-19 while others are still struggling with the complications of a second wave. The Company and its primary operating subsidiary, MTV, have been impacted to varying degrees by this ongoing dynamic but fortunately, the direct impact to operations and the employee base has been limited.

The progression of the pandemic and the success of measures taken to prevent transmission, will influence health and government authorities’ future level of restrictions on business activities within Chile. The Company continues to protect the safety and health of its employees, contractors and the communities in which it operates. Where appropriate, the Company has restricted travel, instructed employees to remote work wherever possible, including at corporate offices. The extent of the effect of the COVID-19 pandemic on the Company’s future business activities is uncertain.

Operations Update

Summary

MTV began construction and development of Papomono Masivo during the fourth quarter of 2020, and following a 12 month construction phase, is expected to ultimately generate underground production in excess of 2,000 tonnes per day while halving unit-mining costs.

MTV resumed operations at Don Gabriel in mid-December. For 2021, MTV will be focusing on processing ore from Don Gabriel, its current inventory and ore supplied by third-party miners and ENAMI, while simultaneously constructing the Papomono Masivo underground mine.

During the three months ended December 31, 2020, the mining operation continued to run in a modified capacity. The smaller Rajo Norte open pit mine continued to run until the end of December 2020 and Don Gabriel resumed operations in December 2020. Supplemental ore was also contributed by third parties and ENAMI. There was limited activity at the Papomono underground site as it was principally in care and maintenance until the Company commenced construction and development activities in November 2020.

Total ore and waste mined in the fourth quarter of 2020 decreased compared to the same quarter in the prior year (114 thousand tonnes in the three months ended December 31, 2020 compared to 2.0 million tonnes in the three months ended December 31, 2019). The reduction in both tonnes of waste moved and ore mined in the fourth quarter of 2020 was driven by the idled mines of Don Gabriel and Papomono during October and November 2020 while the Company focused on processing more economic oxide ore from the Rajo Norte mine, third-party miners and ENAMI, which have a shorter leaching cycle.

Total ore and waste tonnes mined in 2020 decreased compared to the prior year (1.3 million tonnes in the year ended December 31, 2020 compared to 7.4 million tonnes in the year ended December 31, 2019). This is largely due to a significant decrease in tonnes of waste moved in 2020 (0.9 million tonnes compared to 6.2 million tonnes for the year ended December 31, 2019).

Cash cost per pound produced remained consistent at $2.80 for the three months ended December 31, 2020 compared to $2.82 for the three months ended December 31, 2019, despite MTV operating at 24% of capacity. These metrics include a $2.3 million write-down of inventory in the fourth quarter of 2019 and $0.9 million for the three months ended December 31, 2020.

Cash cost per pound produced increased to $2.71 for the year ended December 31, 2020 compared to $2.66 for the year ended December 31, 2019. The increase in cost per pound is largely driven by comparable fixed costs and inventory write-downs spread over fewer copper pounds produced in 2020, compared to 2019.

The Company operated at approximately 34% of its capacity in 2020, which significantly contributed to its gross loss and elevated cash cost per pound produced of copper. It is expected that as the Company increases production during 2022, its gross loss and cash cost per pound produced of copper will reduce meaningfully.

MTV is in the early stages of Papomono Masivo’s construction and development and the Company is monitoring its capital requirements to support MTV through this important stage of growth. The Company is also watching the geopolitical landscape as it can materially impact foreign exchange rates used in planning and modeling MTV’s operations and cash flows.

Production

During the fourth quarter of 2020, MTV produced 2.4 million pounds of 99.999% pure copper cathodes at a cash cost of $2.80 per pound produced (see Non-IFRS Performance Measures) and sold 1.9 million pounds at an average sales price of $3.03 per pound. In accordance with the offtake agreement, MTV sold 40% of its copper cathode production at $2.89 per pound for the three months ended December 31, 2020. MTV had approximately $2.1 million of finished goods inventory at December 31, 2020. MTV produced 4.1 million pounds of copper cathodes at a cash cost of $2.82 per pound and sold 3.3 million pounds at an average sales price of $2.68 per pound in the three months ended December 31, 2019.

Total material crushed in the three months ended December 31, 2020 was 100 thousand tonnes primarily from operations at the smaller Rajo Norte open pit mine. This compares to 364 thousand tonnes in the three months ended December 31, 2019 as mining operations in the current quarter remained primarily in care and maintenance until MTV resumed operations at Don Gabriel mid-December 2020.

For the year ended December 31, 2020, MTV produced 10.8 million pounds of 99.999% pure copper cathodes at a cash cost of $2.71 per pound produced (see Non-IFRS Performance Measures) and sold 8.7 million pounds at an average sales price of $2.58 per pound. MTV produced 15.6 million pounds of copper cathodes at a cash cost of $2.66 per pound and sold 12.6 million pounds at an average sales price of $2.66 per pound in the year ended December 31, 2019.

Total material crushed in the year ended December 31, 2020 was 574 thousand tonnes primarily from operations at Don Gabriel during the first quarter of 2020, and the smaller Rajo Norte open pit. This compares to 1.4 million tonnes crushed in the year ended December 31, 2019, as mining operations at Don Gabriel remained primarily in care and maintenance from midway through the first quarter of 2020 until in mid-December 2020.

Capital Cost Expenditures

Capital expenditures for the year ended December 31, 2020 amounted to $3.4 million and consisted of Papomono Masivo expenditures, pre-stripping waste rock at Don Gabriel, mining equipment and final costs relating to the Salt Leach project. Capital expenditures for the three months ended December 31, 2020 amounted to $2.3 million and primarily consisted of Papomono Masivo expenditures.

Health and Safety

For the three months ended December 31, 2020, there were no Lost-Time Incidents. The Company and MTV devote considerable time and effort to ensure that our workers and contractors return safely to their families after each shift. Our safety statistics are monitored and compared to the country and peer averages, and MTV pro-actively engages in education and assessment to achieve a goal of zero lost-time incidents.

Community and Environment

MTV continues to work with local communities and for the year ended December 31, 2020, the MTV Foundation continued the funding of projects agreed to by the MTV Foundation board, which is largely composed of community representatives to help MTV understand the true needs of its neighbors, such as starting an eco-friendly cooperative at a local school. MTV’s ore purchase program also ensures support from local miners, buying ore from over 26 providers and supporting the development of over 300 small-scale miners through local mining unions.

Financial Results Update

Financial Results

Revenues of $6.0 million for the three months ended December 31, 2020 were generated predominantly from the sale of copper cathodes and, to a lesser extent, tolling charges for mineralized material supplied by ENAMI. Finished goods inventory at December 31, 2020 was approximately $2.1 million. Copper cathodes sold for the three months ended December 31, 2020 of 857 tonnes was lower than the comparative quarter in 2019 of 1,504 tonnes. This was driven by the modified operations implemented in 2020 which reduced operating volumes compared to 2019.

Tonnes of copper sold during the three months ended December 31, 2020 were 647 tonnes lower than the three months ended December 31, 2019 but the favourable price variance mitigated the impact on the gross loss with an increase in realized price from $2.68 per pound for the three months ended December 31, 2019 to $3.03 per pound for the three months ended December 31, 2020.

For three months ended December 31, 2020, the Company reported a quarterly net loss of $6.9 million or $(0.21) per share. This result includes a write-down of inventory, net of reversals of $0.9 million, loss on portfolio investments of $0.4 million and a non-cash loss on a modification of debt of $0.2 million. The modification of debt represents the difference in accounting treatment upon the conversion of a significant portion of MTV’s accounts payable and accrued liabilities to long-term debt as agreed to under the restructuring agreement. Adjusted EBITDA (see Non-IFRS Financial Measures) from continuing operations for the three months ended December 31, 2020 was negative $2.7 million or $(0.08) per share. For the comparable quarter in 2019, the Company reported a net loss of $25.8 million or $(0.76) per share and Adjusted EBITDA from continuing operations of negative $0.4 million or $(0.01) per share.

In 2020, the Company reported a net loss of $30.3 million or $(0.91) per share. This result includes a net loss from discontinued operations of $2.2 million, impairment charges of $7.6 million, an inventory write-down of $4.3 million, gain on modification of debt of $3.2 million and a loss on portfolio investments of $1.7 million. Adjusted EBITDA (see Non-IFRS Financial Measures) from continuing operations for the year ended December 31, 2020 was negative $6.5 million or $(0.19) per share. For 2019, the Company reported a net loss of $52.2 million or $(1.53) per share and Adjusted EBITDA from continuing operations of negative $5.0 million or $(0.15) per share.

In the fourth quarter of 2020, cash used in operating activities was $3.8 million (cash used of $2.4 million before changes in non-cash components of working capital), compared with the fourth quarter of 2019 when cash used in operating activities was $11.3 million (cash used of $19.4 million before changes in non-cash components of working capital).

In 2020, cash used in operating activities was $6.2 million (cash used of $6.8 million before changes in non-cash components of working capital), compared with 2019 when cash used in operating activities was $15.6 million (cash used of $24.9 million before changes in non-cash components of working capital).

The gross loss for 2020 was $10.8 million, or $2.6 million lower than 2019, mainly due to cost reduction initiatives implemented by MTV, despite lower production and a lower average realized copper price. Compared to 2019, total costs have decreased due to cost saving initiatives which included reductions in headcount, idling two mining operations and operating only the smaller Rajo Norte open pit mine, modifying plant shift schedules, purchasing high grade third party ore and maintaining tolling of ENAMI ore which are higher oxide ore and have a faster leach cycle.

Cash Position, Working Capital and Capital

Cash and cash equivalents increased to $12.0 million at December 31, 2020 from $11.6 million at December 31, 2019 as the Company realized cash inflows from proceeds on the disposition of two portfolio investments, the receipt of the first cash distribution from another portfolio investment, and recorded the release of restricted cash of $7.0 million which was mostly offset by cash outflows resulting from the Company’s gross loss and capital expenditures during the year ended December 31, 2020. The majority of cash resided at the Company level and amounted to $9.1 million at December 31, 2020.

The Company’s primary sources of capital resources are comprised of cash and cash equivalents, divestment of its remaining portfolio investments and its loans and borrowings. The Company is substantially leveraged. Although the Company has working capital (see Non-IFRS Financial Measures) of $15.1 million at December 31, 2020, the Company will likely require further financing to meet its current financial obligations, sustain its operations and ongoing capital projects in the normal course, and expand its inventory of reserves and resources.

The Company may seek additional capital at the Company or MTV level to complete exploration and development of its mineral properties and general working capital purposes. MTV currently operates in a high-cost environment. Such financing, if sought, will depend on a number of unpredictable factors, which are often beyond the control of the Company and MTV. These would include the realized price of the actual copper produced from MTV’s operating mines and actual capital expenditures. There can be no assurance that capital will be available to the Company or MTV in the amount required, at any particular time, for any particular period or, if available, obtained on satisfactory terms. Raising capital may be adversely impacted by, amongst other factors: (i) a lack of normally available financing, (ii) current volatile market conditions, (iii) extended and unforeseen issues resulting from the current COVID-19 pandemic, (iv) uncertain water supply conditions in Chile and (v) ongoing geopolitical issues in Chile. To address its financing requirements, the Company may seek financing through joint venture agreements, debt and equity financings, asset sales, rights offerings to existing shareholders or restructuring MTV’s debt and payment terms with critical suppliers.

Investment Portfolio Divestment

During the year ended December 31, 2020, the Company sold its shares in Corsa Coal Corp. and Uranium Royalty Corp (“URC“). Together with a cash distribution received from Beretta Farms Inc. (“Beretta“), the Company recorded total gross proceeds of $3.8 million. Beretta’s shareholders approved the dissolution of Beretta and the distribution of its net cash. As of December 31, 2020, the Company received a cash distribution of $1.0 million and expects to receive a second and final cash distribution in the third quarter of 2021. The Company exercised its URC warrants and sold the resulting equity position in February 2021 for gross proceeds of $0.4 million.

Management expects that the remainder of the investment portfolio will be divested in 2021.

Qualified Persons

The scientific and technical content contained in this news release is taken from the Technical Report entitled “Minera Tres Valles Copper Project, Salamanca, Coquimbo Region, Chile NI 43-101 Technical Report” prepared by Dr Antonio Luraschi, RM CMC, Manager of Metallurgic Development and Senior Financial Analyst, Wood, Mr Sergio Navarrete, RM CMC, Mining Engineer, Wood, Mr Alfonso Ovalle, RM CMC, Mining Engineer, Wood, Mr Michael G. Hester, FAusIMM, Vice President and Principal Mining Engineer, Independent Mining Consultants, Inc., Mr Enrique Quiroga, RM CMC, Mining Engineer, Q&Q Ltda, Mr Gabriel Vera, RM CMC, Metallurgical Process Consultant, GVMetallurgy, and Mr Sergio Alvarado, RM CMC, Consultant Geologist, General Manager and Partner, Geoinvestment Sergio Alvarado Casas E.I.R.L. all of whom were independent qualified persons as defined by NI 43-101 at the time the Technical Report was prepared. The Technical Report is available under the Company’s profile on www.SEDAR.com. Readers are encouraged to read the Technical Report in its entirety.

Notes on Preliminary Economic Assessments

Please note that the PEA Case is preliminary in nature, that it includes inferred mineral resources that are considered too speculative geologically to have the economic considerations applied to them that would enable them to be categorized as mineral reserves, and there is no certainty that the PEA Case will be realized. Mineral resources that are not mineral reserves do not have demonstrated economic viability.

About SRHI Inc.

SRHI is a publicly-listed company based in Toronto, Canada and its principal operating business is its 70% equity interest in the producing copper mine MTV in Salamanca, Chile. For more information about SRHI, please visit www.srhi.ca.

Non-IFRS Performance Measures

“Cash costs”, “Adjusted EBITDA”, “Realized copper price” and “Working Capital” are non-IFRS performance measures. These non-IFRS performance measures do not have a standardized meaning prescribed by IFRS. These measures may differ from those used by, and may not be comparable to such measures as reported by, other issuers. The Company believes that these measures are commonly used by certain investors, in conjunction with conventional IFRS measures, to enhance their understanding of the Company’s performance. For further information and a detailed reconciliation of each non-GAAP measure used in this press release to the most directly comparable IFRS measure, please refer to the Company’s MD&A and accompanying SRHI financial statements filed from time-to-time on SEDAR at www.sedar.com.

Cautionary Statement Regarding Forward-Looking Information

Certain statements in this news release, contain forward-looking information (collectively referred to herein as the “Forward-Looking Statements“) within the meaning of applicable Canadian securities laws. The use of any of the words “expect”, “anticipate”, “continue”, “estimate”, “may”, “will”, “project”, “should”, “believe”, “plans”, “intends” and similar expressions are intended to identify Forward-Looking Statements. In particular, but without limiting the foregoing, this news release contains Forward-Looking Statements pertaining to: future outcomes and expectations related to MTV’s restructuring, the positive impact of the current copper price environment; executing a plan to profitability; expectations regarding the costs, timing and benefits of constructing and mining Papomono Masivo and MTV’s plan during the construction period; MTV’s focus for 2021 and the expected production of the Don Gabriel mine and the timing thereof, sustainability of the mine plan at MTV; impacts of COVID-19 and the Company’s and MTV’s precautions to manage and mitigate same; the potential for the Company’s guarantee of MTV’s indebtedness to be called upon; the expectation for additional capital to be provided by the Company to MTV as well as the quantity, timing and use thereof by MTV; expectations regarding production following construction and ability and timing of generation of cash flow; the future availability of water to MTV’s operations; ongoing geopolitical risks in Chile; expectations regarding the Company’s 2021 guidance, expectations regarding the costs, timing and benefits of the Salt Leach; the long-term mine plan at Papomono and the timing in respect of production growth therefrom; future block caving efforts and the expected benefits therefrom and timing thereof; expectations regarding exploration, the cost, timing and success of such initiatives; and anticipated divestitures of the remaining investment portfolio and timing thereof.

Although SRHI believes that the Forward-Looking Statements are reasonable, they are not guarantees of future results, performance or achievements. A number of factors or assumptions have been used to develop the Forward-Looking Statements, including: there being no additional significant disruptions affecting the development and operation of MTV; the availability of certain consumables (including water) and services and the prices for power and other key supplies being approximately consistent with assumptions in the Technical Studies; labour and materials costs being approximately consistent with assumptions in the Technical Studies; fixed operating costs being approximately consistent with assumptions in the Technical Studies; permitting and arrangements with stakeholders being consistent with current expectations as outlined in the Technical Studies; certain tax rates, including the allocation of certain tax attributes, being applicable to MTV; the availability of financing for the Company’s and MTV’s planned operations and development activities; assumptions made in mineral resource and mineral reserve estimates and the financial analysis based on the mineral reserve estimate and in the case of the Preliminary Economic Assessment, the mineral resource estimate, including (as applicable), but not limited to, geological interpretation, grades, commodity price assumptions, metallurgical performance, extraction and mining recovery rates, hydrological and hydrogeological assumptions, capital and operating cost estimates, and general marketing, political, business and economic conditions, the continued availability of quality management, critical accounting estimates, all terms of the restructuring agreement and facility agreement to which MTV and the Company are parties will be satisfied in the future including no events of default, existing water supply will continue, supplemental water availability will continue, the geopolitical risk of Chile will remain stable, the construction and expansion of mining operations including the Papomono Masivo incline block caving underground mining project, as well as the timing thereof and production therefrom; the timing for the expected production of the Don Gabriel mine; and expected timelines for drawdown and repayment of indebtedness of MTV.

Actual results, performance or achievements could vary materially from those expressed or implied by the Forward-Looking Statements should assumptions underlying the Forward-Looking Statements prove incorrect or should one or more risks or other factors materialize, including: (i) possible variations in grade or recovery rates; (ii) copper price fluctuations and uncertainties; (iii) delays in obtaining governmental approvals or financing; (iv) risks associated with the mining industry in general (e.g., operational risks in development, exploration and production; delays or changes in plans with respect to exploration or development projects or capital expenditures; the uncertainty of estimates and projections relating to mineral reserves, production, costs and expenses; and labour, health, safety and environmental risks) and risks associated with the other portfolio companies’ industries in general; (v) performance of the counterparty to the ENAMI Tolling Contract; (vi) risks associated with investments in emerging markets; (vii) general economic, market and business conditions; (viii) market volatility that would affect the ability to enter or exit investments; (ix) failure to secure additional financing in the future on acceptable terms to the Company, if at all; (x) commodity price fluctuations and uncertainties; (xi) risks associated with catastrophic events, manmade disasters, terrorist attacks, wars and other conflicts, or an outbreak of a public health pandemic or other public health crises, including COVID-19; (xii) those risks disclosed under the heading “Risk Management” in SRHI’s Management’s Discussion and Analysis for the year ended December 31, 2020; and (xiii) those risks disclosed under the heading “Risk Factors” or incorporated by reference into SRHI’s Annual Information Form dated March 3, 2021. See also the cautionary language under “Notes on Preliminary Economic Assessments” above. The Forward-Looking Statements speak only as of the date hereof, unless otherwise specifically noted, and SRHI does not assume any obligation to publicly update any Forward-Looking Statements, whether as a result of new information, future events or otherwise, except as may be expressly required by applicable Canadian securities laws.

Cautionary Note to United States Investors Concerning Estimates of measured, indicated and inferred mineral resources

This news release may use the terms “measured”, “indicated” and “inferred” mineral resources. United States investors are advised that while such terms are recognized and required by Canadian regulations, the United States Securities and Exchange Commission does not recognize them. “Inferred mineral resources” have a great amount of uncertainty as to their existence, and as to their economic and legal feasibility. It cannot be assumed that all or any part of an inferred mineral resource will ever be upgraded to a higher category. Under Canadian rules, estimates of inferred mineral resources may not form the basis of feasibility or other economic studies. United States investors are cautioned not to assume that all or any part of measured or indicated mineral resources will ever be converted into mineral reserves. United States investors are also cautioned not to assume that all or any part of an inferred mineral resource exists or is economically or legally mineable.

For further information:

Michael Staresinic
President and Chief Financial Officer
T: (416) 943-7107
E: [email protected]

Renmark Financial Communications Inc.
Joshua Lavers: [email protected]
T: (416) 644-2020 or (212) 812-7680
www.renmarkfinancial.com

Source: SRHI Inc.

 



Cerecor to Present at Upcoming Investor Conferences

ROCKVILLE, Md. and CHESTERBROOK, Pa., March 04, 2021 (GLOBE NEWSWIRE) — Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in the development and commercialization of treatments for rare and orphan diseases, today announced that Michael F. Cola, President and Chief Executive Officer, will present at two upcoming virtual conferences.

H.C. Wainwright Global Life Sciences Conference
Date: March 9-10, 2021
Pre-Recorded Formal Presentation will be made available on Tuesday, March 9, 2021 at 7:00 AM ET

Oppenheimer’s 31st Annual Healthcare Conference
Date: Wednesday, March 17, 2021
Time: 8:00 AM ET

A live webcast of the presentations can be accessed under “News/Events” page in the Investors section of the Company’s website at www.cerecor.com.

About Cerecor

Cerecor is a biopharmaceutical company focused on becoming a leader in the development and commercialization of treatments for rare and orphan diseases. The company is advancing its clinical-stage pipeline of innovative therapies that address unmet patient needs within rare and orphan diseases. The company’s rare disease pipeline includes CERC-801, CERC-802 and CERC-803, which are in development for congenital disorders of glycosylation and CERC-006, an oral mTORc1/c2 inhibitor in development for the treatment of complex lymphatic malformations. The company is also developing two monoclonal antibodies, CERC-002, and CERC-007. CERC-002 targets the cytokine LIGHT (TNFSF14) and is in clinical development for treatment of severe pediatric-onset Crohn’s disease, and COVID-19 acute respiratory distress syndrome. CERC-007 targets the cytokine IL-18 and is in clinical development for the treatment of Still’s disease (adult onset Still’s disease (AOSD) and systemic juvenile idiopathic arthritis (sJIA)), and multiple myeloma (MM). CERC-006, 801, 802 and 803 have all received Orphan Drug Designation and Rare Pediatric Disease Designation, which makes all four eligible for a priority review voucher upon FDA approval.

For more information about Cerecor, please visit www.cerecor.com.

Forward-Looking Statements

This press release may include forward-looking statements made pursuant to the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts. Such forward-looking statements are subject to significant risks and uncertainties that are subject to change based on various factors (many of which are beyond Cerecor’s control), which could cause actual results to differ from the forward-looking statements. Such statements may include, without limitation, statements with respect to Cerecor’s plans, objectives, projections, expectations and intentions and other statements identified by words such as “projects,” “may,” “might,” “will,” “could,” “would,” “should,” “continue,” “seeks,” “aims,” “predicts,” “believes,” “expects,” “anticipates,” “estimates,” “intends,” “plans,” “potential,” or similar expressions (including their use in the negative), or by discussions of future matters such as: the development of product candidates or products; timing and success of trial results and regulatory review; potential attributes and benefits of product candidates; and other statements that are not historical. These statements are based upon the current beliefs and expectations of Cerecor’s management but are subject to significant risks and uncertainties, including: drug development costs, timing and other risks, including reliance on investigators and enrollment of patients in clinical trials, which might be slowed by the COVID-19 pandemic; regulatory risks; Cerecor’s cash position and the potential need for it to raise additional capital; general economic and market risks and uncertainties, including those caused by the COVID-19 pandemic; and those other risks detailed in Cerecor’s filings with the Securities and Exchange Commission. Actual results may differ from those set forth in the forward-looking statements. Except as required by applicable law, Cerecor expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Cerecor’s expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.

For media and investor inquiries

Chris Brinzey
Westwicke, an ICR Company
[email protected]
339-970-2843

or

Schond L. Greenway
Investor Relations
Chief Financial Officer
Cerecor Inc.
[email protected]
610-522-6200 office



VBL Therapeutics Announces Peer-reviewed Publication of Positive Results of Pre-specified Interim Analysis of OVAL, a Phase 3 Registration Enabling Study of VB-111 in Ovarian Cancer

  • Analysis
    show
    s
    a
    CA-125 response
    of
    at least 58% in the
    VB-111
    treatment arm
  • Published online in Gynecologic Oncology

TEL AVIV, Israel, March 04, 2021 (GLOBE NEWSWIRE) — VBL Therapeutics (Nasdaq: VBLT) today announced the online publication of positive results of the pre-specified interim analysis of the OVAL study, a Phase 3 registration enabling study of VB-111 (ofranergene obadenovec) in recurrent platinum-resistant ovarian cancer. The analysis showed a CA-125 GCIG response rate of 58% or higher in evaluable patients in the VB-111 treatment arm. Based on the results of the interim analysis, the Data and Safety Monitoring Committee (DSMC) recommended continuing the trial as planned. The results were published online in the international peer reviewed journal Gynecologic Oncology (https://doi.org/10.1016/j.ygyno.2021.02.014).

“The goal of this interim analysis was to get a signal of drug activity, using CA-125 as a validated biomarker,” said Bradley J. Monk, M.D., FACOG, FACS, Arizona Oncology (US Oncology Network), University of Arizona College of Medicine, Creighton University School of Medicine, Head of the OVAL steering committee and author on the manuscript. “The intention was to reduce the risk of a negative trial and increase the chance of success. New and novel approaches that have the potential to significantly extend progression free survival or survival are eminently required in platinum-resistant ovarian cancer. VB-111, with its very unique mechanism of action, could be one of those novel approaches and I look forward to the progress of the OVAL trial, which is well designed to test this hypothesis.”

The article reported results of the pre-specified interim analysis in the OVAL study, which reviewed unblinded data and assessed CA-125 response, measured according to the GCIG criteria, in the first 60 enrolled subjects evaluable for CA-125 analysis. Based on the overall response rate in the first 60 patients across both arms of 53%, and assuming balanced randomization and an absolute advantage of 10% or higher to the VB-111 arm, the response rate in the treatment arm (VB-111 in addition to weekly paclitaxel) was calculated to be 58% or higher. In patients who had post-dosing fever, which is a marker for VB-111 treatment, the response rate was 69%. The futility rule determined for this analysis was that the response rate of VB-111 must be greater than the response rate of placebo by at least 10% in order to continue the study. This rule was successfully met.

“We believe VB-111’s unique dual mechanism of action has the potential to prolong life and possibly turn certain cancers into manageable chronic diseases,” said Dror Harats, M.D., Chief Executive Officer of VBL Therapeutics. “The encouraging trajectory of the OVAL trial, not only as reported in this paper but also based on the pre-specified DSMC reviews, makes us hopeful that VB-111 may have a meaningful impact on ovarian cancer.”

About the OVAL study (
NCT03398655
)

OVAL is an international Phase 3 randomized pivotal registration enabling clinical trial that compares a combination of VB-111 and paclitaxel to placebo plus paclitaxel, in patients with platinum-resistant ovarian cancer. The study is planned to enroll approximately 400 patients. OVAL is conducted in collaboration with the GOG Foundation, Inc., an independent international non-profit organization with the purpose of promoting excellence in the quality and integrity of clinical and basic scientific research in the field of gynecologic malignancies.

About VB-111 (
ofranergene
obadenovec
)

VB-111 is an investigational first-in-class, targeted anti-cancer gene-therapy agent that is being developed to treat a wide range of solid tumors. VB-111 is a unique biologic agent that uses a dual mechanism to target solid tumors. Its mechanism combines blockade of tumor vasculature with an anti-tumor immune response. VB-111 is administered as an IV infusion once every 6-8 weeks. It has been observed to be well-tolerated in >300 cancer patients and demonstrated activity signals in an “all comers” Phase 1 trial as well as in three tumor-specific Phase 2 studies. VB-111 has received an Orphan Designation for the treatment of ovarian cancer from the European Commission. VB-111 has also received orphan drug designation in both the US and Europe, and fast track designation in the US for prolongation of survival in patients with rGBM. VB-111 demonstrated proof-of-concept and survival benefit in Phase 2 clinical trials in radioiodine-refractory thyroid cancer and recurrent platinum-resistant ovarian cancer (NCT01711970).

About VBL

Vascular Biogenics Ltd., operating as VBL Therapeutics, is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class treatments for areas of unmet need in cancer and immune/inflammatory indications. VBL has developed three platform technologies: a gene-therapy based technology for targeting newly formed blood vessels with focus on cancer, an antibody-based technology targeting MOSPD2 for anti-inflammatory and immuno-oncology applications, and the Lecinoxoids, a family of small-molecules for immune-related indications. VBL’s lead oncology product candidate, ofranergene obadenovec (VB-111), is an investigational, first-in-class, targeted anti-cancer gene-therapy agent that is being developed to treat a wide range of solid tumors. VB-111 is currently being studied in a VBL-sponsored Phase 3 potential registration trial for platinum-resistant ovarian cancer.


Forward Looking Statements
This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “goal,” “intend,” “look forward to,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “will,” “would” and similar expressions. These forward-looking statements may include, but are not limited to, statements regarding our programs, including VB-111, including their clinical development, therapeutic potential and clinical results. These forward-looking statements are not promises or guarantees and involve substantial risks and uncertainties. Among the factors that could cause actual results to differ materially from those described or projected herein include uncertainties associated generally with research and development, clinical trials and related regulatory reviews and approvals, the risk that historical clinical trial results may not be predictive of future trial results, that our financial resources do not last for as long as anticipated, and that we may not realize the expected benefits of our intellectual property protection. In particular, the DSMC recommendation that the OVAL trial proceed is not assurance that the trial will meet its primary endpoint of overall survival once completed, or that we will obtain positive results to support further development of this candidate.  A further list and description of these risks, uncertainties and other risks can be found in our regulatory filings with the U.S. Securities and Exchange Commission, including in our annual report on Form 20-F for the year ended December 31, 2019, and subsequent filings with the SEC. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. VBL Therapeutics undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise.

CONTACT
:

Burns McClellan for VBL Therapeutics

Lee Roth (investors) / Ryo Imai (media)
[email protected] / [email protected]
+1-212-213-0006

 



Hutchison China MediTech Limited Reports 2020 Full Year Results and Provides Business Updates and Evolves Corporate Identity

Company to Host Annual Results Call & Webcast Today at 1 p.m. GMT / 8 a.m. EST / 9 p.m. HKT

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., March 04, 2021 (GLOBE NEWSWIRE) — Hutchison China MediTech Limited (“HUTCHMED”) (Nasdaq/AIM: HCM), an innovation-driven, commercial-stage biopharmaceutical company, today reports its audited financial results for the year ended December 31, 2020 and provides updates on key clinical and commercial developments.   The Company also intends to seek shareholders’ approval to change its name to HUTCHMED (China) Limited at its forthcoming Annual General Meeting. For more information on the new corporate name, see 2020 Full Year Results & Business Updates—VI. Evolution of Our Corporate Identity.

2020 FULL YEAR RESULTS & BUSINESS UPDATES

“At the heart of HUTCHMED lies a prolific in-house novel drug discovery and development engine that has produced ten clinical-stage drug candidates and a further seven late-stage preclinical assets in oncology and immunology over the past fifteen years.” said Mr. Simon To, Chairman of HUTCHMED. “Our aim is to bring these internally discovered and developed innovations to patients the world-over.”

“To support this strategic objective, we have built an oncology and immunology operation with around 1,200 personnel based mainly in our two core markets, China and the U.S. In China, supported by a robust manufacturing infrastructure, our commercial team is now delivering impressive sales results on our first two oncology drugs, ELUNATE® in metastatic colorectal cancer and the recently launched SULANDA® in neuroendocrine tumors. A New Drug Application was also submitted mid-last year for savolitinib in lung cancer and, subject to approval, it will be our third approved oncology drug and the first-in-class selective MET inhibitor on the market in China.”

“Outside China, our fast expanding international organization, led mainly from the U.S., is developing five un-partnered oncology drug candidates. In 2020, it achieved three U.S. Food and Drug Administration fast track designations and initiated the rolling submission of surufatinib, our first U.S. New Drug Application filing.”  

“Over the next three years, we will continue to grow our R&D and commercial organizations globally to support the anticipated launch of our oncology drugs in China, the U.S. and Europe.”

I. COMMERCIAL OPERATIONS

  • Full year 2021 Oncology/Immunology consolidated revenues guidance $110-130 million (2020 actual: $30.2m) with in-house oncology commercial organization in China now expanded to over 420 personnel (end 2019: about 90) covering over 2,300 oncology hospitals and over 20,000 oncology physicians;
  • ELUNATE

    ®

    (fruquintinib) in-market sales increased 91% to $33.7 million

    1
    (2019: $17.6m), as provided by Lilly2, during 2020 as a result of inclusion in the 2020 China NRDL3;
  • Accelerating sales growth on ELUNATE

    ®
    since Q4 2020 when HUTCHMED assumed responsibility for all on-the-ground medical detailing, promotion and local and regional marketing activities in China;  
(Growth vs. Prior Period)   Lilly Sales Team HUTCHMED Sales Team
  2020 Q1-Q3 2020 Q4 2020 Jan-Feb 2021*
ELUNATE® In-market Sales** $33.7m (+91%) $23.5m (+37%) $10.2m (+2,051%) $14.3m (+116%)
ELUNATE® Revenues consolidated by HUTCHMED*** $20.0m (+85%) $12.8m (+53%) $7.2m (+192%) $10.2m (+269%)

* = Unaudited; ** = Represents total sales to third parties as provided by Lilly; *** = Represents manufacturing fees, commercial service fees and royalties paid by Lilly to HUTCHMED, and sales to other third parties invoiced by HUTCHMED.

  • Launched SULANDA

    ®

    (surufatinib) as a treatment for patients with advanced non-pancreatic NET4 in China in mid-January 2021 within three weeks of approval. Unaudited sales of SULANDA® in January-February 2021, in its first two months on the market, were $4.9 million; and
  • Established our U.S. commercial organization with the recruitment of senior leadership team based in New Jersey to prepare launch readiness for the potential surufatinib U.S. approval in late 2021 or early 2022.

II. REGULATORY ACHIEVEMENTS

China

  • Received China approval for SULANDA

    ®
    from the China NMPA5 as a treatment for patients with advanced non-pancreatic NET in December 2020;
  • Submitted a China NDA

    6

    for savolitinib as a treatment for patients with MET7 Exon 14 skipping alteration NSCLC8. The NDA was accepted in May 2020. Priority Review status was granted in July 2020 and review is underway;
  • Submitted a second China NDA for SULANDA

    ®
    as a treatment for patients with advanced pancreatic NET. The NDA was accepted in September 2020 and review is underway; and
  • IND

    9

    cleared for HMPL-295, a novel ERK10 inhibitor in the MAPK pathway11, in late 2020.

United States & Europe

  • Initiated surufatinib U.S. FDA

    12

    rolling submission of a NDA for the treatment of both pancreatic and non-pancreatic NET in December 2020;
  • Secured U.S. FDA Fast Track Designations for surufatinib for the treatment of both pancreatic and non-pancreatic NET in April 2020;
  • Received scientific advice from the EMA

    13

    CHMP

    14
    for surufatinib for the treatment of both pancreatic and non-pancreatic NET with no MAA15 filing issues identified;
  • Secured U.S. FDA Fast Track Designation for fruquintinib for the treatment of advanced CRC16 in June 2020; and
  • Cleared two U.S. FDA INDs for HMPL-306 in late 2020, in hematological malignancies and solid tumors.

III. CLINICAL DEVELOPMENT ACTIVITIES




Surufatinib



(SULANDA

®

in China), a small molecule inhibitor of VEGFR

17

, FGFR

18

and CSF-1R

19

designed to inhibit tumor angiogenesis and promote the body’s immune response against tumor cells via tumor associated macrophage regulation; approved and launched in China

  • Presented Phase III study in pancreatic NET (SANET-p) (NCT02589821) at the ESMO20 Congress 2020 and published simultaneously in The Lancet Oncology. The study met all primary and secondary endpoints and supported NMPA NDA submission;
  • Presented preliminary data of U.S. Phase Ib NET cohorts (NCT02549937) at the ASCO21 Conference 2020 in heavily pretreated patients with pancreatic or non-pancreatic NET, demonstrating encouraging efficacy in patients refractory or intolerant to AFINITOR® and SUTENT®;
  • Presented pharmacokinetic and safety data of U.S. Phase Ib NET cohorts (NCT02549937) at the AACR22 Conference 2020, demonstrating similar profiles of surufatinib between Chinese and U.S. patients; and
  • Presented Phase I dose-finding study for surufatinib plus TUOYI

    ®
    , Junshi’s23 anti-PD-124 antibody, (NCT04169672) at the AACR Conference 2020. Data demonstrated that surufatinib plus TUOYI® were well tolerated with encouraging antitumor activity in patients with advanced solid tumors. In January 2020, we initiated a Phase II study in nine solid tumor indications in China.

Potential upcoming clinical and regulatory milestones for Surufatinib:

  • Complete the U.S. FDA rolling NDA submission for the treatment of both pancreatic and non-pancreatic NET in the first half of 2021;
  • Initiate a Phase Ib/II study of surufatinib in combination with tislelizumab (NCT04579757), BeiGene’s25 PD-1 antibody, in the U.S. in the first half of 2021;
  • Submit the EU MAA for the treatment of both pancreatic and non-pancreatic NET in mid-2021;
  • Present Phase II data for the SULANDA

    ®

    plus TUOYI

    ®
    combination in select indications in mid-2021;
  • Receive China approval for patients with advanced pancreatic NET which may occur as early as the second half of 2021; and
  • Initiate Phase III pivotal studies for the SULANDA

    ®

    plus TUOYI

    ®
    combination in select indications in the second half of 2021 and beyond.




Fruquintinib



(ELUNATE

®

in China),
a highly selective small molecule inhibitor of VEGFR 1/2/3 designed to improve kinase selectivity to minimize off-target toxicity and thereby improve tolerability; approved and launched in China

  • Initiated a global Phase III registration study (NCT04322539), the FRESCO-2 study, in refractory metastatic CRC. FRESCO-2 is expected to enroll over 680 patients from over 150 sites in 14 countries. The first patient was dosed in September 2020 in the U.S.;
  • Presented preliminary data of U.S. Phase I/Ib colorectal cancer cohorts (NCT03251378) at the ESMO Congress 2020 in heavily pretreated metastatic CRC patients, demonstrating encouraging efficacy and tolerability in patients refractory or intolerant to STIVARGA® and LONSURF®;
  • Completed second planned interim data review for a Phase III registration study (NCT03223376), the FRUTIGA study, in advanced gastric cancer. Based on preset criteria the IDMC26 and Joint Steering Committees recommended that the trial continue with a sample size increase to ~700 patients; and
  • Initiated a Phase II study for fruquintinib in combination with TYVYT

    ®
    , Innovent’s27 PD-1 antibody, in four solid tumor indications (NCT03903705) in Q4 2020.

Potential upcoming clinical and regulatory milestones for Fruquintinib:

  • Initiate a Phase Ib/II study in the U.S. for fruquintinib in combination with tislelizumab (NCT04577963) in patients with advanced, refractory triple negative breast cancer in the first half of 2021;
  • Present Phase Ib U.S. expansion data in metastatic CRC (NCT03251378) in mid-2021;
  • Present preliminary Phase Ib data for fruquintinib plus TYVYT

    ®

    (NCT04179084) and
    fruquintinib plus geptanolimab
    (NCT03977090) in CRC in mid-2021;  
  • Initiate pivotal studies for the ELUNATE

    ®

    plus anti-PD-1 antibody combination in select indications in the second half of 2021;
  • Complete enrollment of the FRESCO-2 study (NCT04322539) in refractory metastatic CRC in late-2021; and
  • Complete enrollment of the FRUTIGA study (NCT03223376) in advanced gastric cancer in late-2021;




Savolitinib


,

a highly selective small molecule inhibitor of MET being developed broadly across MET-driven patient populations in lung and gastric cancer and renal cell carcinoma  

  • Presented Phase II registration study (NCT02897479) for savolitinib in MET Exon 14 skipping mutation patients at the ASCO Conference 2020 which met study endpoints and supported NMPA NDA submission;
  • Presented Phase II data for the CALYPSO study (NCT02819596) for savolitinib in combination with IMFINZI®, AstraZeneca’s28 PD-L129 antibody, in PRCC30 patients at the ASCO GU31 Conference 2020 demonstrating encouraging synergy in efficacy and tolerability in line with single agent safety profiles;
  • Presented Phase III data for the SAVOIR study (NCT03091192) for savolitinib in MET positive PRCC patients at the ASCO Conference 2020 showing a clear trend to superiority in efficacy and tolerability versus SUTENT® in first 60 patient data; and
  • Presented final Phase II data for TATTON (NCT02143466) at WCLC32 2020, a global exploratory study in NSCLC aiming to recruit patients with MET amplification who had progressed after prior treatment with EGFR33 inhibitors. TATTON clearly confirmed the importance of the savolitinib plus TAGRISSO® combination.

Potential upcoming clinical and regulatory milestones for Savolitinib:

  • Potential receipt of approval in China for the treatment of patients with MET Exon 14 skipping alteration NSCLC which may occur as early as Q2 2021, enabling a $25 million first sale milestone payment from AstraZeneca. If approved, savolitinib would be the first-in-class selective MET inhibitor in China;
  • Initiate global Phase III pivotal studies for the savolitinib plus IMFINZI

    ®
    combination in MET positive PRCC in mid-2021;
  • Initiate Phase II study with potential for registration intent for savolitinib in metastatic gastric cancer in China in mid-2021;
  • Conclude the SAVANNAH Phase II study (NCT03778229) for the savolitinib plus TAGRISSO® combination in NSCLC patients harboring EGFR mutation and MET amplification or overexpression. SAVANNAH will inform final regulatory, biomarker and dose regimen strategy for global Phase III development in the second half of 2021; and
  • Initiate two further pivotal Phase III studies in China in NSCLC patients in the second half of 2021.




HMPL-689,



an investigative and highly selective small molecule inhibitor of PI3K
δ

34

designed to address the gastrointestinal and hepatotoxicity associated with currently approved and clinical-stage PI3Kδ inhibitors 

  • Presented Phase I dose escalation data (NCT03128164) for HMPL-689 in patients in China with relapsed/refractory lymphoma at the ASH35 Annual Meeting 2020 demonstrating encouraging efficacy and tolerability profile.

Potential upcoming clinical and regulatory milestones for HMPL-689:

  • Complete Phase Ib expansion study (NCT03128164) and present interim data in the second half of 2021;
  • Initiate Phase II studies with potential for registration intent in China in multiple relapsed/refractory non-Hodgkin’s lymphoma indications during 2021;
  • Complete Phase I dose escalation in the U.S. and Europe (NCT03786926) in Q2 2021 and initiate Phase Ib expansion studies in multiple non-Hodgkin’s lymphoma indications; and
  • Complete U.S. FDA regulatory discussions in the second half of 2021 followed by the initiation of registration intent studies in indolent non-Hodgkin’s lymphoma by the end of 2021.




HMPL-523




,

an investigative and highly selective small molecule inhibitor of Syk

36

, an important component of the B-cell receptor signaling pathway,
for the treatment of hematological cancers and immune disease

  • Completed enrollment of Phase I dose escalation study (NCT03779113) in the U.S. and Europe; and
  • Completed enrollment of Phase I/Ib study (NCT03951623) in China of HMPL-523 in ITP37.

Potential upcoming clinical and regulatory milestones for HMPL-523:

  • Initiate a Phase III study in ITP in China in the second half of 2021.




HMPL-453,



an investigative and highly selective small molecule inhibitor of FGFR 1/2/3

  • Initiated a Phase II study (NCT04353375) in China in patients with advanced IHCC38 with FGFR239 fusion that had failed at least one line of systemic therapy.




HMPL-306,



an investigative and highly selective small molecule inhibitor of IDH1/2

40

designed to address resistance to the currently marketed IDH inhibitors

  • Initiated a Phase I dose escalation study (NCT04272957) in China in patients with relapsed or refractory hematological malignancies with an IDH1 and/or IDH2 mutation.

Potential upcoming clinical and regulatory milestones for HMPL-306:

  • Initiate a Phase I dose escalation study in the U.S. in patients with relapsed or refractory hematological malignancies with an IDH1 and/or IDH2 mutation in the first half of 2021; and
  • Initiate a Phase I dose escalation study in the U.S. in patients with solid tumors with an IDH1 and/or IDH2 mutation in the first half of 2021.




HMPL-295




,

an investigative and highly selective small molecule inhibitor of ERK in the MAPK pathway with the potential to address intrinsic or acquired resistance from upstream mechanisms such as RAS-RAF-MEK.

Potential upcoming clinical and regulatory milestones for HMPL-295:

  • Initiate a Phase I study in China in mid-2021




Discovery



, our in-house scientific team has been responsible for the discovery of all ten of our clinical drug candidates including our two approved oncology drugs ELUNATE

®

and SULANDA

®

Potential upcoming discovery milestones:

  • IND-enabling toxicity studies are underway for three additional in-house discovered oncology drug candidates, two small molecules and one antibody. If the outcomes of these studies are as we anticipate, we will follow with IND submissions during 2021.

IV. MANUFACTURING OPERATIONS

  • Received surufatinib update to drug manufacturing license at our Suzhou manufacturing facility, following the NMPA approval in December 2020; and
  • Broke ground in December 2020 on our $130 million new Shanghai manufacturing facility designed to support a five-fold increase in small molecule drug product manufacturing capacity relative to our existing Suzhou facilities. We plan also that in the future the Shanghai facility will also establish scale biologics manufacturing capability.

V. OTHER CORPORATE DEVELOPMENTS

  • Announced a clinical collaboration agreement with BeiGene in May 2020 to evaluate combining surufatinib and fruquintinib with BeiGene’s anti-PD-1 antibody tislelizumab, for the treatment of various solid tumor cancers, in the U.S., Europe, China and Australia;
  • Announced a land compensation agreement in June 2020 with the Guangzhou government for the return of the remaining 34-year land-use rights on an unused plot of land under our HBYS41 joint venture in consideration for cash compensation of up to approximately $100 million; and
  • Announced a strategic partnership with Inmagene

    42
    in January 2021 to further develop four novel preclinical drug candidates discovered by HUTCHMED for the potential treatment of multiple immunological diseases.

VI. EVOLUTION OF OUR CORPORATE IDENTITY

Today we announce the consolidation of the two corporate identities that we have used since our inception. Hutchison China MediTech, or Chi-Med, has been used as our group identity, while Hutchison MediPharma has been the identity of our novel drug R&D43 operations under which our oncology products have been developed and are now being marketed. We believe now is the right time to consolidate to a single and ubiquitous corporate identity that captures the history and brand equity we have built over the past twenty years.

Therefore, we have chosen to rename ourselves HUTCHMED. The brand HUTCHMED will immediately replace Chi-Med as our abbreviated name. We plan to formally change our group company name at our Annual General Meeting in April 2021, and the names of our key subsidiary companies over the balance of 2021. Our ticker symbol, HCM, will remain unchanged on the Nasdaq Global Select Market and the AIM market of the London Stock Exchange. We have also changed our website to www.hutch-med.com. The information required pursuant to AIM Rule 26 may be found at this address.

VII. IMPACT OF COVID-19

The COVID-19 outbreak initially posed some challenges to our operations in 2020 resulting from restrictions in travel. Our teams adapted quickly and were able to minimize the effect across our businesses. We will continue to closely monitor the evolving situation.

FULL YEAR 2020 FINANCIAL RESULTS

Change in Segment Reporting:

As a consequence of our recent commercialization of both ELUNATE® and SULANDA® and the possible approval and launch of savolitinib during 2021, we have decided to change the manner in which we report segment results in our financial statements. Effective from the year ended December 31, 2020, we will report two segments, (1) Oncology/Immunology, covering all activities related to oncology/immunology including sales, marketing, manufacturing and research and development with respect to our drugs and drug candidates; and (2) Other Ventures, which includes all other HUTCHMED businesses. We have retrospectively revised prior period segment information to conform to current period presentation in the financial information contained in this announcement.

Cash, Cash Equivalents and Short-Term Investments were $435.2 million as of December 31, 2020 compared to $217.2 million as of December 31, 2019.

  • Adjusted Group (non-GAAP44) net cash flows excluding financing activities were -$78.4 million (2019: -$82.3m) mainly due to Oncology/Immunology R&D spending and partially offset by dividends received from our non-consolidated joint ventures totaling $86.7 million (2019: $28.1m); and
  • Net cash generated from financing activities in 2020 totaled $296.4 million (2019: -$1.5m) mainly resulting from a Nasdaq follow-on offering in January 2020 and two private placements to General Atlantic45 and CPP Investments46 completed in July and November 2020 respectively.

Revenues for the year ended December 31, 2020 was $228.0 million compared to $204.9 million in 2019.

  • Oncology/Immunology consolidated revenues were $30.2 million (2019: $26.8m) comprised of $20.0 million (2019: $10.8m) in manufacturing revenues, promotion and marketing service revenues and royalties from the commercial sale of ELUNATE®; and $10.2 million (2019: $16.0m) in research and development service fee revenues primarily from AstraZeneca and Lilly; and
  • Other Ventures consolidated revenues increased 11% (11% at CER47) to $197.8 million (2019: $178.1m) mainly due to continued sales growth of third-party prescription drug products.

Net Expenses
for the year ended December 31, 2020 were $353.7 million compared to $310.9 million in 2019.

  • Cost of Sales were $188.5 million (2019: $160.2m), the majority of which was the cost of third-party prescription drug products marketed through our profitable Other Ventures;
  • R&D Expenses were $174.8 million (2019: $138.2m) mainly as a result of an expansion in the development of our ten novel oncology drug candidates. With six now in global development, our rapidly scaling international clinical and regulatory operations in the U.S. and Europe incurred expenses of $63.3 million (2019: $21.7m) while R&D expense in China was stable at $111.5 million (2019: $116.5m);
  • SG&A

    48

    Expenses were $61.3 million (2019: $52.9m) primarily due to increases in staff costs and share-based compensation to support expanding operations. This included the build-up of a large-scale national oncology commercial infrastructure in China to support the launch of SULANDA® and the assumption of commercial responsibility on ELUNATE®; and
  • Other Items

    49
    generated net income of $70.9 million (2019: $40.4m) resulting primarily from an increase in our share of equity in the earnings from equity investees under our Other Ventures in China which delivered solid underlying net income growth of 7% (9% at CER) in 2020 and also benefited from a one-time land compensation gain of $28.8 million (2019: nil).

Net Loss
attributable to HUTCHMED for the year ended December 31, 2020 was $125.7 million compared to $106.0 million in 2019.

  • As a result, the net loss attributable to HUTCHMED in 2020 was $0.18 per ordinary share / $0.90 per ADS50 compared to net loss attributable to HUTCHMED of $0.16 per ordinary share / $0.80 per ADS, in 2019.

FINANCIAL SUMMARY

Condensed Consolidated Balance Sheet Data
(in $’000)

    As of December 31,
    2020   2019
Assets        
Cash and cash equivalents and short term investments   435,176   217,168
Accounts receivable   47,870   43,254
Other current assets   47,694   56,600
Property, plant and equipment   24,170   20,855
Investments in equity investees   139,505   98,944
Other non-current assets   29,703   28,301
Total assets   724,118   465,122
Liabilities and shareholders’ equity        
Accounts payable   31,612   23,961
Other payables, accruals and advance receipts   120,882   81,624
Long-term bank borrowings   26,861   26,818
Other liabilities   25,814   19,816
Total liabilities   205,169   152,219
Total Company’s shareholders’ equity   484,116   288,012
Non-controlling interests   34,833   24,891
Total liabilities and shareholders’ equity   724,118   465,122

Condensed Consolidated Statement of Operations Data

(in $’000, except share and per share data)

  Year Ended December 31,
  2020     2019  
Revenues:      
Oncology/Immunology – Marketed Products 19,953     10,766  
Oncology/Immunology – R&D 10,262     16,026  
Oncology/Immunology consolidated revenues 30,215     26,792  
Other Ventures 197,761     178,098  
        Total revenues 227,976     204,890  
Expenses:      
Costs of revenues (188,519 )   (160,152 )
Research and development expenses (174,776 )   (138,190 )
Selling and general administrative expenses (61,349 )   (52,934 )
Total expenses (424,644 )   (351,276 )
Loss from Operations (196,668 )   (146,386 )
Other income 6,934     5,281  
Loss before income taxes and equity in earnings of equity investees (189,734 )   (141,105 )
Income tax expense (4,829 )   (3,274 )
Equity in earnings of equity investees, net of tax 79,046     40,700  
Net loss (115,517 )   (103,679 )
Less: Net income attributable to non-controlling interests (10,213 )   (2,345 )
Net loss attributable to HUTCHMED (125,730 )   (106,024 )

Losses per share attributable to HUTCHMED – basic and diluted

(0.18 )   (0.16 )
Number of shares used in per share calculation – basic and diluted 697,931,437     665,683,145  

Losses per ADS attributable to HUTCHMED – basic and diluted

(0.90 )   (0.80 )
Number of ADSs used in per share calculation – basic and diluted 139,586,287     133,136,629  

All amounts are expressed in U.S. dollar currency unless otherwise stated.

FINANCIAL GUIDANCE

We provide select Financial Guidance for 2021 below reflecting expected commercial progress on ELUNATE® and SULANDA® as well as the potential launch of savolitinib in mid-2021. While we do not provide net cash flow guidance for 2021, we do expect an increase in investment to support the many new potential registration studies we plan this year as well as the continued expansion of our organization in China, the U.S. and Europe. 

To support our growth plans, we continue to actively evaluate non-core assets divestment opportunities as well as monitor market conditions for seeking further listings on other stock exchanges such as Hong Kong and Shanghai.

  2020

Actual
2021

Guidance
     
Oncology/Immunology consolidated revenues $30.2 million $110 – 130 million


Use of Non-GAAP Financial Measures and Reconciliation
– References in this announcement to adjusted Group net cash flows excluding financing activities and financial measures reported at CER are based on non-GAAP financial measures. Please see the “Use of Non-GAAP Financial Measures and Reconciliation” below for further information relevant to the interpretation of these financial measures and reconciliations of these financial measures to the most comparable GAAP measures, respectively.


Conference Call and Audio Webcast Presentation Scheduled Today at 1 p.m. GMT / 8 a.m. EST / 9 p.m. HKT
– Investors may participate in the call as follows: +44 20 3194 0569 (U.K.) / +1 646 722 4977 (U.S.) / +852 3027 6500 (Hong Kong), or access a live audio webcast of the call via HUTCHMED’s website at www.hutch-med.com/event/.

Additional dial-in numbers are also available at HUTCHMED’s website. Please use participant access code “38028560#.”

This announcement in its entirety is available at: http://ml.globenewswire.com/Resource/Download/693f5edc-0aa1-45cd-b3ab-090bed0e68e3

FINANCIAL STATEMENTS

HUTCHMED will today file with the U.S. Securities and Exchange Commission its Annual Report on Form 20-F.

ANNUAL GENERAL MEETING

The Annual General Meeting of HUTCHMED will be held on Wednesday, April 28, 2021. Notice of the 2021 Annual General Meeting will be published and issued to shareholders in due course.

About HUTCHMED

HUTCHMED (Nasdaq/AIM: HCM) is an innovative, commercial-stage, biopharmaceutical company committed, over the past twenty years, to the discovery and global development of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. It has advanced ten cancer drug candidates from discovery into clinical studies around the world and has an extensive commercial infrastructure in its home market of China. For more information, please visit: www.hutch-med.com.

CONTACTS

Investor Enquiries  
Mark Lee, Senior Vice President +852 2121 8200
Annie Cheng, Vice President +1 (973) 567 3786
   
Media Enquiries  
Americas – Brad Miles, Solebury Trout +1 (917) 570 7340 (Mobile)
[email protected]
Europe – Ben Atwell / Alex Shaw, FTI Consulting +44 20 3727 1030 / +44 7771 913 902 (Mobile) / +44 7779 545 055 (Mobile)
[email protected]
Asia – Joseph Chi Lo / Zhou Yi, Brunswick +852 9850 5033 (Mobile), [email protected] /
+852 9783 6894 (Mobile), [email protected]
   
Nominated Advisor  
Freddy Crossley / Atholl Tweedie, Panmure Gordon (UK) Limited +44 (20) 7886 2500

References

Unless the context requires otherwise, references in this announcement to the “Group,” the “Company,” “HUTCHMED,” “HUTCHMED Group,” “we,” “us,” and “our,” mean Hutchison China MediTech Limited and its consolidated subsidiaries and joint ventures unless otherwise stated or indicated by context.


Past Performance and Forward-Looking Statements

The performance and results of operations of the Group contained within this announcement are historical in nature, and past performance is no guarantee of future results of the Group. This announcement contains forward-looking statements within the meaning of the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by words like “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” “pipeline,” “could,” “potential,” “first-in-class,” “designed to,” “objective,” “guidance,” “pursue,” or similar terms, or by express or implied discussions regarding potential drug candidates, potential indications for drug candidates or by discussions of strategy, plans, expectations or intentions. You should not place undue reliance on these statements. Such forward-looking statements are based on the current beliefs and expectations of management regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that any of our drug candidates will be approved for sale in any market, or that any approvals which are obtained will be obtained at any particular time, or that any such drug candidates will achieve any particular revenue or net income levels. In particular, management’s expectations could be affected by, among other things: unexpected regulatory actions or delays or government regulation generally; the uncertainties inherent in research and development, including the inability to meet our key study assumptions regarding enrollment rates, timing and availability of subjects meeting a study’s inclusion and exclusion criteria and funding requirements, changes to clinical protocols, unexpected adverse events or safety, quality or manufacturing issues; the inability of a drug candidate to meet the primary or secondary endpoint of a study; the impact of the COVID-19 pandemic or other health crises in China or globally; the inability of a drug candidate to obtain regulatory approval in different jurisdictions or gain commercial acceptance after obtaining regulatory approval; global trends toward health care cost containment, including ongoing pricing pressures; uncertainties regarding actual or potential legal proceedings, including, among others, actual or potential product liability litigation, litigation and investigations regarding sales and marketing practices, intellectual property disputes, and government investigations generally; and general economic and industry conditions, including uncertainties regarding the effects of the persistently weak economic and financial environment in many countries and uncertainties regarding future global exchange rates. For further discussion of these and other risks, see HUTCHMED’s filings with the U.S. Securities and Exchange Commission and on AIM. HUTCHMED is providing the information in this announcement as of this date and does not undertake any obligation to update any forward-looking statements as a result of new information, future events or otherwise.

In addition, this announcement contains statistical data and estimates that HUTCHMED obtained from industry publications and reports generated by third-party market research firms. Although HUTCHMED believes that the publications, reports and surveys are reliable, HUTCHMED has not independently verified the data and cannot guarantee the accuracy or completeness of such data. You are cautioned not to give undue weight to this data. Such data involves risks and uncertainties and are subject to change based on various factors, including those discussed above.

Inside Information

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No 596/2014.

REFERENCES AND ABBREVIATIONS

1
        
Sales of Elunate® to third parties invoiced by Lilly were $32.7 million (2019: $17.6m) & invoiced by HUTCHMED were $1.0 million (2019: nil).

2
        
Lilly = Eli Lilly and Company

3
        
NRDL = National Reimbursement Drug List

4
        
NET = Neuroendocrine tumors

5
        
NMPA = National Medical Products Administration

6
        
NDA = New Drug Application

7
        
MET = Mesenchymal epithelial transition receptor

8
        
NSCLC = Non-small cell lung cancer

9
        
IND = Investigational new drug application

10
        
ERK = Extracellular signal-regulated kinase

11
        
MAPK pathway = RAS-RAF-MEK-ERK signaling cascade

12
        
FDA = Food and Drug Administration

13
        
EMA = European Medicines Agency

14
        
CHMP = Committee for Medicinal Products for Human Use

15
        
MAA = Marketing Authorisation Application

16
        
CRC = Colorectal cancer

17
        
VEGFR = Vascular endothelial growth factor receptor

18
        
FGFR = Fibroblast growth factor receptor

19
        
CSF-1R = Colony stimulating factor-1 receptor

20
        
ESMO = European Society for Medical Oncology Annual Congress

21
        
ASCO = American Society of Clinical Oncology Annual Meeting

22
        
AACR = American Association of Cancer Research Annual Meeting

23
        
Junshi = Shanghai Junshi Biosciences Co. Ltd.

24
        
PD-1 = Programmed Cell Death Protein-1

25
        
BeiGene = BeiGene Ltd.

26
        
IDMC = Independent data monitoring committee

27
        
Innovent = Innovent Biologics, Inc.

28
        
AstraZeneca = AstraZeneca AB (publ)

29
        
PD-L1 = Programmed death-ligand 1

30
        
PRCC = Papillary renal cell carcinoma

31
        
ASCO GU = American Society of Clinical Oncology Genitourinary Symposium

32
        
WCLC = World Conference on Lung Cancer

33
        
EGFR = Epidermal growth factor receptor

34
        
PI3Kδ = Phosphoinositide 3-kinase delta

35
        
ASH = American Society of Hematology Annual Meeting

36
        
Syk = Spleen tyrosine kinase

37
        
ITP = Immune thrombocytopenia purpura

38
        
IHCC = Intrahepatic cholangiocarcinoma

39
        
FGFR2 = Fibroblast growth factor receptor 2

40
        
IDH1/2 = Isocitrate dehydrogenase 1/2

41
        
HBYS = Hutchison Whampoa Guangzhou Baiyunshan Chinese Medicine Company Limited

42
        
Inmagene = Inmagene Biopharmaceuticals Co. Ltd.

43
        
R&D = Research and development

44
        
GAAP = Generally Accepted Accounting Principles

45
        
General Atlantic = General Atlantic Singapore HCM Pte. Ltd

46
        
CPP Investments = Canada Pension Plan Investment Board

47
        
We also report changes in performance at constant exchange rate (“CER”) which is a non-GAAP measure. Please refer to “Use of Non-GAAP Financial Measures and Reconciliation” below for further information relevant to the interpretation of these financial measures and reconciliations of these financial measures to the most comparable GAAP measures.

48
        
SG&A = Selling, general and administrative

49
        
Other items = includes other income, income tax expense, equity in earnings of equity investees, net of tax and net income attributable to non-controlling interests

50
        
ADS = American depositary share

USE OF NON-GAAP FINANCIAL MEASURES AND RECONCILIATION

In addition to financial information prepared in accordance with U.S. GAAP, this announcement also contains certain non-GAAP financial measures based on management’s view of performance including:

  • Adjusted Group net cash flows excluding financing activities
  • CER

Management uses such measures internally for planning and forecasting purposes and to measure the HUTCHMED Group’s overall performance. We believe these adjusted financial measures provide useful and meaningful information to us and investors because they enhance investors’ understanding of the continuing operating performance of our business and facilitate the comparison of performance between past and future periods. These adjusted financial measures are non-GAAP measures and should be considered in addition to, but not as a substitute for, the information prepared in accordance with U.S. GAAP. Other companies may define these measures in different ways.

Adjusted Group net cash flows excluding financing activities: We include the change in short-term investments for the period to the change in cash and cash equivalents for the period, and exclude the net cash (generated from)/used in financing activities for the period to derive our adjusted Group net cash flows excluding financing activities. We believe the presentation of adjusted Group net cash flows excluding financing activities provides useful and meaningful information about the change in our cash resources excluding those from financing activities which may present significant period-to-period differences.

CER: We remove the effects of currency movements from year-to-year comparisons by retranslating the current year’s performance at previous year’s foreign currency exchange rates. Because we have significant operations in China, the RMB to U.S. dollar exchange rates used for translation may have a significant effect on our reported results. We believe the presentation at CER provides useful and meaningful information because it facilitates year-to-year comparisons of our results and increases the transparency of our underlying performance.

Reconciliation of GAAP change in cash and cash equivalents and short-term investments to Adjusted Group net cash flows excluding financing activities:

$’millions   2020   2019  
Cash and cash equivalents and short-term investments at end of year   435.2   217.2  
Excludes: Cash and cash equivalents and short-term investments at
beginning of year
  (217.2 ) (301.0 )
Excludes: Net cash (generated from)/used in financing activities for the year   (296.4 ) 1.5  
Adjusted Group net cash flows excluding financing activities   (78.4 ) (82.3 )

Reconciliation of GAAP revenues, net income attributable to HUTCHMED from Other Ventures to CER:

$’millions (except %)

Year Ended   Change Amount   Change %
December 31, 2020 December 31, 2019   Actual CER Exchange effect   Actual CER Exchange effect
Consolidated Revenues Other Ventures 197.8 178.1   19.7   20.5   (0.8
)
  11
%
11
%
0
%
                     
                     
Consolidated net income attributable to HUTCHMED                    
                     
Excluding one-time HBYS land compensation gain                    
  Other Ventures 44.0 41.5   2.5 3.3 (0.8
)
  6
%
8
%
-2
%
  — Consolidated entities 2.8 2.9   (0.1) (0.1) –    -5% -5% 0%
   — Equity investees 41.2 38.6   2.6 3.4 (0.8)   7% 9% -2%
                     
Land compensation gain                    
— HBYS 28.8   28.8 28.8  



Akoustis to Present at the Tenth Annual Susquehanna Technology Conference March 9-11, 2021

Charlotte, N.C., March 04, 2021 (GLOBE NEWSWIRE) — Akoustis Technologies, Inc. (NASDAQ: AKTS) (“Akoustis” or the “Company”), an integrated device manufacturer (IDM) of patented bulk acoustic wave (BAW) high-band RF filters for mobile and other wireless applications, announced today that senior management will attend the Tenth Annual Susquehanna Technology Conference which is being held virtually between March 9-11, 2021.

Meetings will take place virtually given the ongoing call for social distancing due to the Covid-19 pandemic. Investors that would like to schedule a meeting with Akoustis management should contact their Susquehanna representative or Akoustis’ investor relations at [email protected].

Akoustis’ high frequency, high performance XBAW® process and filters are experiencing growing interest as the Company entered production in multiple markets in calendar 2020, including 5G network infrastructure, high-band WiFi and phased-array radar applications.

Akoustis is actively delivering volume production of its WiFi 6 tandem filter solutions, shipping multiple 5G small cell XBAW® filter solutions, delivering initial designs of its new 5G mobile filter solutions to multiple customers and is now entering the market with its WiFi 6E coexistence XBAW® filter solutions. Company management expects continued top-line growth moving forward and given the growing backlog of commercially available RF filter products and technology aimed at large and growing markets, it plans to significantly expand the capacity at its New York fab.

Akoustis has added 15 filters to its product catalog including a 5.6 GHz WiFi filter, a 5.2 GHz WiFi filter, a 5.5 GHz WiFi-6E filter, a 6.5 GHz WiFi 6E filter, three small cell 5G network infrastructure filters including two Band n77 filters and one Band n79 filter, a 3.8 GHz filter and five S-Band filters for defense phased-array radar applications, a 3.6 GHz filter for the CBRS 5G infrastructure market and a C-Band filter for the unmanned aircraft systems (UAS) market. The Company is also developing several new filters for the sub-7 GHz bands targeting 5G mobile device, network infrastructure, WiFi CPE and defense markets.

About Akoustis Technologies, Inc.

Akoustis® (http://www.akoustis.com/) is a high-tech BAW RF filter solutions company that is pioneering next-generation materials science and MEMS wafer manufacturing to address the market requirements for improved RF filters – targeting higher bandwidth, higher operating frequencies and higher output power compared to incumbent polycrystalline BAW technology deployed today. The Company utilizes its proprietary XBAW® manufacturing process to produce bulk acoustic wave RF filters for mobile and other wireless markets, which facilitate signal acquisition and accelerate band performance between the antenna and digital back end. Superior performance is driven by the significant advances of high-purity, single-crystal and associated piezoelectric materials and the resonator-filter process technology which drives electro-mechanical coupling and translates to wide filter bandwidth. 

Akoustis plans to service the fast growing multi-billion-dollar RF filter market using its integrated device manufacturer (IDM) business model. The Company owns and operates a 120,000 sq. ft. ISO-9001:2015 registered commercial wafer-manufacturing facility located in Canandaigua, NY, which includes a class 100 / class 1000 cleanroom facility – tooled for 150-mm diameter wafers – for the design, development, fabrication and packaging of RF filters, MEMS and other semiconductor devices. Akoustis Technologies, Inc. is headquartered in the Piedmont technology corridor near Charlotte, North Carolina.

Forward-Looking Statements

This document includes “forward-looking statements” within the meaning of Section 27A of the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, that are intended to be covered by the “safe harbor” created by those sections. These forward-looking statements include, but are not limited to, statements about our estimates, expectations, beliefs, intentions, plans or strategies for the future (including our possible future results of operations, business strategies, competitive position, potential growth opportunities, potential market opportunities and the effects of competition), and the assumptions underlying such statements. Forward-looking statements include all statements that are not historical facts and typically are identified by use of terms such as “may,” “might,” “would,” “will,” “should,” “could,” “project,” “expect,” “plan,” “strategy,” “anticipate,” “attempt,” “develop,” “help,” “believe,” “estimate,” “predict,” “intend,” “forecast,” “seek,” “potential,” “continue,” “future,” and similar words (including the negative of any of the foregoing), although some forward-looking statements are expressed differently. Forward-looking statements are neither historical facts nor assurances of future results, performance, events or circumstances. Instead, these forward-looking statements are based on management’s current beliefs, expectations and assumptions and are subject to risks and uncertainties. Factors that could cause actual results to differ materially from those currently anticipated include, without limitation, risks relating to our ability to obtain adequate financing and sustain our status as a going concern; our limited operating history; the results of our research and development activities, including uncertainties relating to semiconductor process manufacturing; the development of our XBAW® technology and products presently under development and the anticipated timing of such development; our ability to protect our intellectual property rights that are valuable to our business, including patent and other intellectual property rights; our reliance on third parties to complete certain processes in connection with the manufacture of our products; product quality and defects; existing or increased competition; our ability to successfully manufacture, market and sell products based on our technologies; the ability to achieve qualification of our products for commercial manufacturing in a timely manner and the size and growth of the potential markets for any products so qualified; our ability to successfully scale our New York wafer fabrication facility and related operations while maintaining quality control and assurance and avoiding delays in output; the rate and degree of market acceptance of any of our products; our ability to achieve design wins from current and future customers; contracting with customers and other parties with greater bargaining power and agreeing to terms and conditions that may adversely affect our business; risks related to doing business in foreign countries; any security breaches or other disruptions compromising our proprietary information and exposing us to liability; our ability to raise funding to support operations and the continued development and qualification of our products and the technologies underlying them); and the impact of a pandemic or epidemic or a natural disaster, including the COVID-19 pandemic, on our operations, financial condition and the worldwide economy, including its impact on our ability to access the capital markets; our ability to maintain effective internal control over financial reporting; and our ability to obtain and maintain the Trusted Foundry accreditation of our New York wafer fabrication facility. These and other risks and uncertainties are described in more detail in the Risk Factors and Management’s Discussion and Analysis of Financial Condition and Results of Operations sections of the Company’s most recent Annual Report on Form 10-K and in subsequently filed Quarterly Reports on Form 10-Q. Considering these risks, uncertainties and assumptions, the forward-looking statements regarding future events and circumstances discussed in this document may not occur, and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. You should not rely upon forward-looking statements as predictions of future events. The forward-looking statements included in this document speak only as of the date hereof and, except as required by law, we undertake no obligation to update publicly or privately any forward-looking statements, whether written or oral, for any reason after the date of this document to conform these statements to new information, actual results or to changes in our expectations.



Contact:

COMPANY:
Tom Sepenzis
Akoustis Technologies
VP of Corporate Development & IR
(980) 689-4961
[email protected]

The Del Mar Consulting Group, Inc.
Robert B. Prag, President
(858) 794-9500
[email protected]

Telesat Reports Results for the Quarter and Year Ended December 31, 2020

OTTAWA, March 04, 2021 (GLOBE NEWSWIRE) — Telesat today announced its financial results for the three-month and one-year periods ended December 31, 2020. All amounts are in Canadian dollars and reported under International Financial Reporting Standards (“IFRS”) unless otherwise noted.

For the year ended December 31, 2020, Telesat reported consolidated revenue of $820 million, a decrease of 10% ($90 million) compared to the same period in 2019. When adjusted for changes in foreign exchange rates, revenue decreased 10% ($87 million) compared to 2019. The revenue decrease was due to lower short-term services provided to other satellite operators, a reduction of service for a broadcast customer, the completion of the non-cash amortization of a significant financing component of an agreement, and the impact of the COVID-19 pandemic, particularly on customers serving the aeronautical and maritime markets. Operating expenses were $181 million, an increase of 9% ($15 million) from 2019. Operating expenses increased because of higher bad debt expense related to customers impacted by the COVID-19 pandemic, higher professional fees related to Telesat’s proposed roll-up transaction, higher in-orbit insurance expense, and higher wages due principally to increased headcount to support the development of the Telesat Lightspeed Low Earth Orbit (LEO) satellite constellation. Foreign exchange rate changes did not have a material impact on operating expenses. Adjusted EBITDA1 was $653 million, a decrease of 14% ($109 million) or, when adjusted for foreign exchange rates, a decrease of 14% ($106 million). The Adjusted EBITDA margin1 for 2020 was 79.6%, compared to 83.7% in 2019.

For the year ended December 31, 2020, net income was $246 million, compared to net income of $187 million for 2019. The increase in net income for the year was principally the result of a 2019 loss on refinancing which did not re-occur in 2020, lower interest expense and a lower non-cash loss on financial instruments, partially offset by lower operating income and lower non-cash foreign exchange gains arising from the translation of Telesat’s U.S. dollar denominated debt into Canadian dollars.

For the quarter ended December 31, 2020, consolidated revenue was $202 million, a decrease of 8% ($18 million) compared to the same period in 2019. Adjusted for foreign exchange rate changes, revenue declined 7% ($16 million). The decrease was primarily due to the non-re-occurrence in 2020 of short-term services provided to other satellite operators.

Operating expenses of $47 million for the quarter were 7% ($3 million) lower than the same period in 2019. Adjusted EBITDA1 for the quarter was $160 million, a decrease of 8% ($15 million) compared to the same period in 2019. Adjusted for changes in foreign exchange rates, Adjusted EBITDA1 declined by 7% ($13 million) compared to the fourth quarter of 2019. The Adjusted EBITDA margin1 for the fourth quarter of 2020 was 79.5%, compared to 79.6% in the same period in 2019.

Telesat’s net income for the quarter was $255 million compared to net income of $3 million for the quarter ended December 31, 2019. The $253 million difference was the result of a non-re-occurring loss on refinancing in 2019, higher non-cash gains on foreign exchange arising principally from the translation of Telesat’s U.S. dollar denominated debt into Canadian dollars in the fourth quarter of 2020, and lower interest expense.

“Our full year results reflect certain factors that we anticipated, namely the non-renewal in late 2019 of a contract with a North American DTH customer and the end of the revenue amortization period of a contract with another customer, as well as certain factors that we did not anticipate, namely a paucity of opportunities to provide short-term satellite services to other satellite operators and the COVID-19 pandemic,” commented Dan Goldberg, Telesat’s President and CEO. “These anticipated and unanticipated factors account for our reduced revenue and Adjusted EBITDA1. Having said that, we continued to generate strong cash flows and maintained high operating margins and a substantial contractual backlog, which provides high visibility into our future performance.”

Goldberg added: “I am particularly pleased with the progress we made last year and in the past few weeks on laying the foundations for our future growth, including our recent announcement that we selected Thales Alenia Space to build our revolutionary Lightspeed global broadband LEO satellite constellation and the announcement that the Government of Quebec will be making a significant investment in that important program. Lightspeed will give Telesat and our customers a decisive competitive advantage in serving the enterprise broadband connectivity market, helping to bridge the digital divide around the world and fueling our growth for years to come. I am also pleased with the progress we are making in transforming Telesat into a publicly listed company and in extracting value from our desirable C-band spectrum rights, both of which will help us fund our compelling growth plans. In sum, last year was a productive one for Telesat and we remain focused on maintaining the strong momentum we have as we execute our growth plans going forward.”

Business Highlights

• At December 31, 2020:

  • Telesat had contracted backlog2 for future services of approximately $2.7 billion.
  • Fleet utilization was 81% across Telesat’s fleet.

• Telesat Lightspeed Constellation

  • On February 9, 2021, Telesat announced that it entered into an agreement with Thales Alenia Space (TAS) to be the prime manufacturer of the Telesat Lightspeed constellation and that TAS and its affiliate Telespazio have made a Lightspeed capacity commitment in connection with the agreement. Under the terms of the agreement, the parties have provided for the advancement of the program while the financing for the project is being finalized.
  • On February 18, 2021, Telesat announced that it entered into a Memorandum of Understanding (MOU) with the Government of Québec for an investment of $400 million into Telesat Lightspeed. Under the terms of the MOU, the investment by the Government of Québec will consist of $200 million in preferred equity as well as a $200 million loan. It is expected that a final agreement will be completed in the coming months.

•  Public Company

  • On November 23, 2020, Telesat Canada announced that it entered into an agreement with Loral Space & Communications Inc. (NASDAQ: LORL) (Loral) and Public Sector Pension Investment Board pursuant to which Telesat Canada and Loral will become subsidiaries of Telesat Corporation, a new publicly traded Canadian incorporated and controlled company.  The shares of Telesat Corporation will be listed on the Nasdaq Global Select Market at the closing of the transaction and Telesat is also considering a listing on a Canadian stock exchange. The transaction is expected to close in the second or third quarter of 2021, subject to the receipt of required regulatory approvals, the approval of Loral’s stockholders, and other customary conditions.

• Repurposing of C-Band Spectrum

  • The U.S. Federal Communications Commission (FCC) has adopted a plan to repurpose a portion of the C-band spectrum presently used by satellite operators for 5G. In doing so, the FCC provided that Telesat would receive as much as US$344.4 million from the repurposing of C-band spectrum provided that we can meet certain requirements. We currently believe we can meet all the requirements to receive the US$344.4 million.
  • A similar repurposing of C-band spectrum is currently underway in Canada, with the Government of Canada launching a public consultation on repurposing C-band spectrum in August 2020. In the consultation document, in addition to its own proposal, the Government of Canada included a proposal put forward by Telesat whereby Telesat — the sole satellite operator licensed to use C-band in Canada — would accelerate, and be fully responsible for, the clearing of a portion of the C-band spectrum so that it could be used for 5G. In return, Telesat would be compensated for clearing and repurposing the spectrum. Comments were submitted to the government on October 26, 2020, and Reply Comments were submitted on November 30, 2020. Telesat anticipates a decision in 2021.

• Telesat Lightspeed Asset Transfers

  • In December 2020, in connection with the financing of the Telesat Lightspeed Constellation, Telesat transferred to certain unrestricted subsidiaries assets relating to the Telesat Lightspeed network, including NGSO spectrum authorizations, U.S. market access rights, certain IP, certain fixed assets and certain contracts, and C-band assets, including Canadian C-band licenses and U.S. C-band market access rights, together with the right to receive proceeds from the repurposing thereof. Concurrently with these transfers, Telesat contributed US$193 million in cash to Telesat LEO Holdings Inc., an unrestricted subsidiary of Telesat.
  • Immediately prior to the asset transfers, Telesat prepaid outstanding term loans under its Amended Senior Secured Credit Facilities in an aggregate principal amount of US$341.4 million.

Telesat’s annual report on Form 20-F for the year ended December 31, 2020, has been filed with the United States Securities and Exchange Commission (“SEC”) and may be accessed on the SEC’s website at www.sec.gov.

Conference Call

Telesat has scheduled a conference call on Thursday, March 4, 2021, at 10:30 a.m. ET to discuss its financial results for the three month and one year periods ended December 31, 2020. The call will be hosted by Daniel S. Goldberg, President and Chief Executive Officer, and Andrew Browne, Chief Financial Officer, of Telesat.

Prior to the commencement of the call, Telesat will post a news release containing its financial results on its website (www.telesat.com) under the tab “Investors” and the heading “Investor News”.

Dial-in Instructions:
The toll-free dial-in number for the teleconference is +1 800 952 5114. Callers outside of North America should dial +1 416 641 6104. The conference event service confirmation number is: 4353885. The access code is 6924580 followed by the number sign (#). Please allow at least 15 minutes prior to the scheduled start time to connect to the teleconference.

Dial-in Audio Replay:
A replay of the teleconference will be available one hour after the end of the call on March 4, 2021 until 11:59 p.m. ET on March 18, 2021. To access the replay, please call +1 800 408 3053. Callers from outside North America should dial +1 905 694 9451. The access code is 4368450 followed by the number sign (#).

About Telesat

Backed by a legacy of engineering excellence, reliability and industry-leading customer service, Telesat is one of the largest and most successful global satellite operators. Telesat works collaboratively with its customers to deliver critical connectivity solutions that tackle the world’s most complex communications challenges, providing powerful advantages that improve their operations and drive profitable growth.

Continuously innovating to meet the connectivity demands of the future, Telesat Lightspeed, the company’s Low Earth Orbit (LEO) satellite network, will be the first and only LEO network optimized to meet the rigorous requirements of telecom, government, maritime and aeronautical customers. Operating under its global priority Ka-band spectrum rights, Telesat Lightspeed will redefine global satellite connectivity with ubiquitous, affordable, high-capacity links with fibre-like speeds.

Privately held and headquartered in Ottawa, Canada with offices and facilities around the world, Telesat’s principal shareholders are Canada’s Public Sector Pension Investment Board and Loral Space & Communications Inc. (NASDAQ: LORL). For more information, visit www.telesat.com.

Forward-Looking Statements Safe Harbor

This news release contains statements that are not based on historical fact and are ”forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. When used in this news release, the words “future”, expected”, “continuing”, “plans” and “will”, or other variations of these words or other similar expressions are intended to identify forward-looking statements and information. Actual results may differ materially from the expectations expressed or implied in the forward-looking statements as a result of known and unknown risks and uncertainties. Detailed information about some of the known risks and uncertainties is included in the “Risk Factors” section of Telesat Canada’s Annual Report on Form 20-F for the fiscal year ended December 31, 2020 which can be obtained on the SEC website.

Known risks and uncertainties include but are not limited to: risks associated with operating satellites and providing satellite services, including satellite construction or launch delays, launch failures, in-orbit failures or impaired satellite performance, the ability to successfully deploy an advanced global LEO satellite constellation, the availability of government and/or other funding for the LEO satellite constellation, the receipt of proceeds in relation to the re-allocation of C-band spectrum, volatility in exchange rates, risks and expense associated with becoming a publicly listed company the ability to expand our existing satellite utilization and risks associated with domestic and foreign government regulation. The foregoing list of important factors is not exhaustive. The information contained in this news release reflects Telesat’s beliefs, assumptions, intentions, plans and expectations as of the date of this news release. Except as required by law, Telesat disclaims any obligation or undertaking to update or revise the information herein.

Contact
Michael Bolitho
Telesat
+1.613.748.8828
[email protected]
 

Telesat Canada

Consolidated Statements of Income

For the periods ended December 31

    Three months   Twelve Months
(in thousands of Canadian dollars)     2020       2019       2020       2019  
Revenue   $ 201,908     $ 220,164     $ 820,468     $ 910,893  
Operating expenses     (47,162 )     (50,628 )     (180,874 )     (165,499 )
Depreciation     (50,066 )     (55,685 )     (216,885 )     (242,966 )
Amortization     (4,289 )     (4,741 )     (17,195 )     (23,277 )
Other operating gains (losses), net     31       (715 )     (215 )     (862 )
Operating income     100,422       108,395       405,299       478,289  
Interest expense     (47,843 )     (64,092 )     (203,760 )     (258,261 )
Loss on refinancing           (151,919 )           (151,919 )
Interest and other (expense) income     (1,471 )     4,553       5,196       20,043  
Gain (loss) on changes in fair value of financial instruments 25,769       14,689       (13,115 )     (49,672 )
Gain on foreign exchange     146,693       65,413       47,605       163,840  
Income (loss) before tax     223,570       (22,961 )     241,225       202,320  
Tax recovery (expense)     31,453       25,470       4,353       (15,122 )
Net income   $ 255,023     $ 2,509     $ 245,578     $ 187,198  
                                 

Telesat Canada

Consolidated Balance Sheets

(in thousands of Canadian dollars)   December 31, 2020   December 31, 2019
             
Assets            
Cash and cash equivalents   $ 818,378   $ 1,027,222
Trade and other receivables     51,928     64,062
Other current financial assets     448     210
Prepaid expenses and other current assets     22,861     43,724
Total current assets     893,615     1,135,218
Satellites, property and other equipment     1,318,526     1,458,933
Deferred tax assets     79,912     12,412
Other long-term financial assets     53,425     57,730
Other long-term assets     9,922     8,264
Intangible assets     779,190     802,791
Goodwill     2,446,603     2,446,603
Total assets   $ 5,581,193   $ 5,921,951
             
Liabilities            
Trade and other payables   $ 30,091   $ 26,247
Other current financial liabilities     35,880     38,281
Other current liabilities     96,155     72,315
Current indebtedness         24,408
Total current liabilities     162,126     161,251
Long-term indebtedness     3,187,152     3,688,391
Deferred tax liabilities     325,893     348,762
Other long-term financial liabilities     35,499     42,511
Other long-term liabilities     410,587     435,711
Total liabilities     4,121,257     4,676,626
             
Shareholders’ Equity            
Share capital     155,698     154,895
Accumulated earnings     1,266,514     1,031,055
Reserves     37,724     59,375
Total shareholders’ equity     1,459,936     1,245,325
Total liabilities and shareholders’ equity   $ 5,581,193   $ 5,921,951
             

Telesat Canada

Consolidated Statements of Cash Flows

For the years ended December 31

(in thousands of Canadian dollars)   2020   2019
Cash flows from operating activities              
Net income   $ 245,578     $ 187,198  
Adjustments to reconcile net income to cash flows from operating activities            
Depreciation     216,885       242,966  
Amortization     17,195       23,277  
Tax (recovery) expense     (4,353 )     15,122  
Interest expense     203,760       258,261  
Interest income     (7,668 )     (20,268 )
Gain on foreign exchange     (47,605 )     (163,840 )
Loss on changes in fair value of financial instruments     13,115       49,672  
Share-based compensation     12,500       16,035  
Loss on disposal of assets     215       862  
Loss on refinancing           151,919  
Other     (58,784 )     (100,078 )
Income taxes paid, net of income taxes received     (53,443 )     (95,455 )
Interest paid, net of interest received     (179,972 )     (176,112 )
Operating assets and liabilities     15,018       (13,942 )
Net cash from operating activities     372,441       375,617  
               
Cash flows used in investing activities              
Satellite programs     (75,902 )     (3,668 )
Purchase of property and other equipment     (17,060 )     (8,345 )
Purchase of intangible assets     (30 )     (27,597 )
Net cash used in investing activities     (92,992 )     (39,610 )
               
Cash flows used in financing activities              
Repayment of indebtedness     (453,592 )     (3,743,465 )
Proceeds from indebtedness           3,786,082  
Payment of early redemption premium           (43,940 )
Payment of debt issue costs           (28,082 )
Payments of principal on lease liabilities     (1,793 )     (1,252 )
Satellite performance incentive payments     (9,031 )     (9,644 )
Government grant received     14,185        
Dividends paid on Director Voting preferred shares     (10 )     (20 )
Net cash used in financing activities     (450,241 )     (40,321 )
                 
Effect of changes in exchange rates on cash and cash equivalents     (38,052 )     (36,897 )
                 
(Decrease) increase in cash and cash equivalents     (208,844 )     258,789  
Cash and cash equivalents, beginning of year     1,027,222       768,433  
Cash and cash equivalents, end of year   $ 818,378     $ 1,027,222  
                 

Telesat’s Adjusted EBITDA margin(1):

    Three months ended December 31,


  Twelve months ended December 31,
(in thousands of Canadian dollars) (unaudited)   2020   2019


  2020   2019


Net income   $ 255,023     $ 2,509     $ 245,578     $ 187,198  
Tax (recovery) expense     (31,453 )     (25,470 )     (4,353 )     15,122  
(Gain) loss on changes in fair value of financial instruments     (25,769 )     (14,689 )     13,115       49,672  
Gain on foreign exchange     (146,693 )     (65,413 )     (47,605 )     (163,840 )
Interest and other expense (income)     1,471       (4,553 )     (5,196 )     (20,043 )
Interest expense     47,843       64,092       203,760       258,261  
Loss on refinancing           151,919             151,919  
Depreciation     50,066       55,685       216,885       242,966  
Amortization     4,289       4,741       17,195       23,277  
Other operating (gains) losses, net     (31 )     715       215       862  
Non-recurring compensation expenses(3)     385       180       1,261       1,260  
Non-cash expense related to share-based compensation     5,340       5,487       12,500       16,035  
Adjusted EBITDA   $ 160,471     $ 175,203     $ 653,355     $ 762,689  
                         
Revenue   $ 201,908     $ 220,164     $ 820,468     $ 910,893  
Adjusted EBITDA Margin     79.5 %     79.6 %     79.6 %     83.7 %
                                 

End Notes

1  The common definition of EBITDA is “Earnings Before Interest, Taxes, Depreciation and Amortization.” In evaluating financial performance, Telesat uses revenue and deducts certain operating expenses (including share-based compensation expense and unusual and non-recurring items, including restructuring related expenses) to obtain operating income before interest expense, taxes, depreciation and amortization (“Adjusted EBITDA”) and the Adjusted EBITDA margin (defined as the ratio of Adjusted EBITDA to revenue) as measures of Telesat’s operating performance.

Adjusted EBITDA allows Telesat and investors to compare Telesat’s operating results with that of competitors exclusive of depreciation and amortization, interest and investment income, interest expense, taxes and certain other expenses. Financial results of competitors in the satellite services industry have significant variations that can result from timing of capital expenditures, the amount of intangible assets recorded, the differences in assets’ lives, the timing and amount of investments, the effects of other income (expense), and unusual and non-recurring items. The use of Adjusted EBITDA assists Telesat and investors to compare operating results exclusive of these items. Competitors in the satellite services industry have significantly different capital structures. Telesat believes the use of Adjusted EBITDA improves comparability of performance by excluding interest expense.

Telesat believes the use of Adjusted EBITDA and the Adjusted EBITDA margin along with IFRS financial measures enhances the understanding of Telesat’s operating results and is useful to Telesat and investors in comparing performance with competitors, estimating enterprise value and making investment decisions. Adjusted EBITDA as used here may not be the same as similarly titled measures reported by competitors. Adjusted EBITDA should be used in conjunction with IFRS financial measures and is not presented as a substitute for cash flows from operations as a measure of Telesat’s liquidity or as a substitute for net income as an indicator of Telesat’s operating performance.

2 Remaining performance obligations, which Telesat refers to as contracted revenue backlog (‘‘backlog’’), represents Telesat’s expected future revenue from existing service contracts (without discounting for present value) including any deferred revenue that Telesat will recognize in the future in respect of cash already received. The calculation of the backlog reflects the revenue recognition policies adopted under IFRS 15. The majority of Telesat’s contracted revenue backlog is generated from contractual agreements for satellite capacity.

3 Includes severance payments and special compensation and benefits for executives and employees.



Landos Biopharma Announces Positive Results from a Phase 1 Study of NX-13 in Healthy Volunteers

NX-13 was well tolerated with no reported serious adverse events

All primary and secondary endpoints in the Phase 1 study of NX-13 were met

Landos expects to initiate a Phase 1b trial of NX-13 in patients with ulcerative colitis (UC) later this year

BLACKSBURG, Va., March 04, 2021 (GLOBE NEWSWIRE) — Landos Biopharma (NASDAQ: LABP), a clinical-stage biopharmaceutical company focused on the discovery and development of therapeutics for patients with autoimmune diseases, today announced NX-13, the Company’s first-in-class novel, orally administered therapeutic candidate for the treatment of inflammatory bowel disease (IBD), has successfully met all primary and secondary endpoints in a Phase 1 study. The data showed that NX-13 was well tolerated following evaluation of multiple doses over one and seven days compared with placebo.

“The favorable results from this trial underscore the promise of NX-13’s novel multimodal mechanism of action, targeting the NLRX1 pathway locally in the GI tract, and its potential to bring a new approach to treating patients with IBD,” commented Josep Bassaganya-Riera, Chairman, President and Chief Executive Officer of Landos. “As a part of our growing franchise of gut-restricted, oral therapeutics for ulcerative colitis (UC) and Crohn’s disease (CD) with novel immunometabolic mechanisms, we are excited that NX-13 met all primary and secondary endpoints in this first-in-humans study.”

“By using Landos’ powerful LANCE discovery and development platform, we have identified three novel mechanisms of therapeutic efficacy (LANCL2, NLRX1 and PLXDC2) and developed seven novel product candidates around those targets. Our lead product candidates (BT-11 and NX-13) are in clinical testing and our development pipeline currently targets up to 14 autoimmune disease indications. We are pleased that it took only 18 months for NX-13 to advance from discovery to Phase 1 clinical testing and we are looking forward to initiating a Phase 1b trial in patients with UC later this year,” commented Raquel Hontecillas, PhD, Chief Scientific Officer of Landos.

The Phase 1 trial was a randomized, double-blind, placebo-controlled single and multiple ascending dose study designed to evaluate the safety, tolerability and pharmacokinetics of NX-13, which was orally administered. The single ascending dose arm consisted of 35 healthy volunteers in a total of five cohorts (250 to 4,000 mg). The multiple ascending dose arm consisted of 21 healthy volunteers enrolled in a total of three cohorts (1,000 to 4,000 mg). Within each cohort in both dose arms, five participants received NX-13 and two participants received placebo. Across the eight cohorts, no SAEs were reported. The maximum tolerated dose was identified to be 10-fold greater than the anticipated therapeutic dose.

Following the positive results from the Phase 1 study, Landos plans to initiate a Phase 1b trial of NX-13 in patients with ulcerative colitis in 2021. Additionally, building on the success of the LANCE computational platform in BT-11 and NX-13, Landos anticipates filing at least three new INDs in 2021.

About NX-13

NX-13 is a first-in-class, orally active, gut-restricted, small molecule therapeutic candidate for the treatment of inflammatory bowel disease. NX-13 targets NLRX1, a mitochondria-associated receptor with the ability to modulate immune responses. By activating the NLRX1 pathway, NX-13 is designed to increase oxidative phosphorylation in immune cells, reduces differentiation of effector CD4-positive T cells, and decrease production of inflammatory cytokines.

About Landos Biopharma

Landos Biopharma is a clinical-stage biopharmaceutical company focused on the discovery and development of oral therapeutics for patients with autoimmune diseases that are the first to target new mechanisms of action, including the LANCL2, NLRX1 and PLXDC2 immunometabolic pathways. Landos Biopharma’s core expertise is in the development of therapeutic candidates targeting novel pathways at the interface of immunity and metabolism. Lead asset BT-11 is a novel, oral, gut-restricted small molecule therapeutic candidate for the treatment of ulcerative colitis and Crohn’s disease that targets the LANCL2 pathway. NX-13 is a novel, oral, gut-restricted compound for the treatment of inflammatory bowel disease, which targets the NLRX1 pathway. Additional candidates are in development for the treatment of lupus nephritis, rheumatoid arthritis, multiple sclerosis, and diabetes.

Contacts:

Thomas Hoffmann (investors)
Solebury Trout
646-378-2931
[email protected]

Hannah Gendel (media)
Solebury Trout
646-378-2943
[email protected]

 



Hatch celebrates 65th anniversary with release of new campaign, “Positive change: leadership for a better world”

Global engineering, project management, and professional services firm shares insights on how the world has changed and where it is headed

Mississauga, Canada, March 04, 2021 (GLOBE NEWSWIRE) — Global engineering, project management, and professional services firm, Hatch, is celebrating its 65th anniversary with the release of a new campaign, “Positive change: leadership for a better world.” The campaign includes a report, curated video content, and a microsite, which detail how, in the last sixty-five years since the firm’s inception, they have changed to meet their clients’ evolving needs.

Hatch was founded in the 1950s as an engineering and technology consultancy firm primarily serving the metals and infrastructure sectors. The company’s first projects included work on the subway tunnels beneath Toronto for the Toronto Transit Commission and work for Québec Iron & Titanium’s (now Rio Tinto) metallurgical complex in Sorel-Tracy, Québec. Hatch has pioneered, innovated, and raised the bar in the industries in which we work, partnering with clients in the pursuit of positive change, while simultaneously growing the company to more than 9,000 employees worldwide.

With these commemorative assets, Hatch leaders from around the globe examine how the world is facing its toughest challenges, how our clients have responded, and how the role of engineers has transformed to deliver holistic solutions. The experts tackle issues such as climate change, food accessibility and security, the energy transition, digitization, urbanization, and community engagement, providing their insights into how these challenges are transforming how we work together and lending insight into their visions for the future.

“As ‘entrepreneurs with a technical soul,’ Hatch is uniquely positioned and obligated to tackle the toughest challenges facing our clients, and our world today. Some of the major themes occurring in our market sectors include the energy transformation towards renewable power and decarbonization, infrastructure development towards large, livable cities with sustainable resources, and a shift towards a new, digitized world. The climate change and sustainability solutions we identify in partnership with our clients will not only positively impact their businesses, but the communities and environments we all live and work in,” said John Bianchini, Hatch’s chairman and CEO.

“Communities, industries, engineers, and advisors will need to come together and demonstrate the leadership that’s required to build the world we want and can sustain. Tackling the challenges of the future will require solutions that are bold, innovative, and challenge the status quo,” added Martin Doble, Hatch’s global managing director of Strategy and Development.

To explore these new insights, click here

-30-

Additional quotes:  

“One thing is certain: change is inevitable. Engineering is about solving problems, and the world won’t have a shortage of those anytime soon. Never before has society needed engineers, scientists, technologists, and advisors more. Never before has it been more important for businesses to work collaboratively with their host communities and truly engage the people who live in them. But whatever the future may bring, I remain confident that we are ready to take on whatever the next few decades have in store–for us, our clients, and our communities,” asserted John Bianchini, chairman and CEO.

“We are in an era of global transition. Our world needs leaders, visionaries, and realists to create practical solutions that will bring a sustainable and resilient future to meet the aspirations of humankind. At Hatch, we are determined and committed to bring our leadership, ingenuity, energy, and strong values to work to achieve positive change together,” said Martin Doble, Hatch’s global managing director of Strategy and Development

About Hatch

Whatever our clients envision, our engineers can design and build. With over six decades of business and technical experience in the mining, energy, and infrastructure sectors, we know your business and understand that your challenges are changing rapidly. We respond quickly with solutions that are smarter, more efficient, and innovative. We draw upon our 9,000 staff with experience in over 150 countries to challenge the status quo and create positive change for our clients, our employees, and the communities we serve.

Find out more on www.hatch.com.



Lindsay Janca
Hatch
19054034199
[email protected]

Sugarbud Provides Corporate Update and Comments on 2021 Outlook

CALGARY, Alberta, March 04, 2021 (GLOBE NEWSWIRE) — Sugarbud Craft Growers Corp. (TSXV:SUGR, SUGR.WT, SUGR.WS, SUGR.DB) (“Sugarbud” or the “Company“) is pleased to provide a corporate operating update and comments regarding its outlook for 2021.


Corporate Operating Update

“2020 was a pivotal and productive period for the Company’s overall scale up and growth plans,” stated Sugarbud CEO John Kondrosky. “In addition to receiving our amended sales license for dried cannabis in Q3 2020, the Company formally entered the adult-use recreational cannabis market in earnest in Q4 2020 – after securing important supply agreements with the Provinces of Saskatchewan, Alberta and British Columbia. In the final weeks of the year, we received our first $1.0 million in purchase orders,” continued Mr. Kondrosky.

Subsequent to year end, the Company entered into supply agreements with the Province of Ontario and the Yukon Territory.

With a clear line of sight on revenue generating supply and harvests now occurring once every month and a half at its Stavely cultivation facility, the Company has firmly established steady state commercial operations and is now operating at a level sufficient to meet the Company’s positive revenue and EBITDA objectives for 2021.

“We are pleased with our progress to date after our first full year of operations and believe that we have established a strong platform to rapidly accelerate the Company’s continued growth in 2021,” concluded Mr. Kondrosky.

2021 Outlook – Quality Over Quantity

The Canadian adult-use recreational cannabis market continues to evolve at a rapid pace as consumer buying practices and preferences become more refined and informed.

Despite volatility in the sector, the Company expects that the growth and momentum the recreational cannabis sector saw building in the latter half of 2020 will continue in 2021. The Company believes that the most significant drivers of growth will be a holistic commitment to premium quality and consumer satisfaction over volume.

“Sugarbud puts the consumer at the center of everything we do. Our experience, market data and both retailer and consumer feedback confirm that our focus is both well-aimed and critical to the success of the Sugarbud brand,” stated Mr. Kondrosky.

Rather than focus solely on general categories such as “value priced” or “premium products”, the Company believes that a relentless pursuit and commitment to total value and consumer satisfaction across multiple product and consumer preference attributes is the more prudent pathway forward towards a sustainable and profitable business.

“We are producing exceptional top-quality products for an intelligent consumer,” Mr. Kondrosky notes. “We recognize that our consumers have different interests, diverse hobbies, busy jobs and are pursuing all kinds of things to make their lives even fuller. We understand that we must work hard to find and earn a place in their busy day”, continued Mr. Kondrosky.

“Consequently, we have set a high bar for ourselves and spend a lot of time making sure that what we produce measures up to consumer expectations,” concluded Mr. Kondrosky.

The Company believes that the recent drive to split the market between the binary choice of “price/value” versus “premium”, is short-sighted. Along with a focus on singular product attributes such as potency alone, Sugarbud believes this does a disservice to the consumer.

“As the market continues to mature, we believe that the time and effort we are putting into providing our target consumers with a balanced approach to total product quality at a fair price will drive sustainable growth. This overarching commitment to consumer excellence will play a fundamental role in eliminating the need for consumers to continue to access the black market,” added Mr. Kondrosky.

“Based on positive feedback received from the market to date, we believe that we are well-positioned to continue to expand our market share and accelerate revenue growth in 2021,” concluded Mr. Kondrosky.

Critical Operating Priorities for 2021

Operationally the Company has the existing capacity to achieve its business objectives for 2021 and has the flexibility and agility to rapidly expand capacity within its existing licensed Stavely facility to meet an increase in demand should it be required.

The Company maintains an agile and scalable operating model and has several facility build-out options which it can quickly deploy, when market demand requires.

In order to fully realize significant growth opportunities and continue to expand market share in 2021, the Company will continue to leverage existing operational capacity and expand commercial capacity for growth by:

READ Q1 2021 CORPORATE PRESENTATION HERE

https://www.globenewswire.com/NewsRoom/AttachmentNg/0469cd5f-ada9-4225-bbd4-b030de1b5027


About Sugarbud

Sugarbud is an Alberta-based, consumer-driven boutique craft cannabis company focused on the cultivation and production of superior, select-batch, craft cannabis products. Our vision and mission are to become a trusted and well-respected consumer brand renowned for providing exceptional high-quality craft cannabis products to legal markets by delighting the most discerning of cannabis consumers.

The Sugarbud Craft Cannabis Collection offers consumers “Hand-Crafted Cannabis for a New Era”. The Company is proudly Albertan and is proud to share Western Canada’s long tradition of exceptional craft cannabis with the most discerning of enthusiasts. Sugarbud strives to define the intersection of product craftsmanship, quality, and value for consumers in the Canadian craft cannabis space.

John Kondrosky

Chief Executive Officer

Sugarbud Craft Growers Corp.
Phone: (604) 499-7847
E-mail: [email protected]

Investor Relations Contact
Chris Moulson
Chief Financial Officer
Sugarbud Craft Growers Corp.
Tel: (778) 388-8700
E-mail: [email protected]

Websites:
http://www.sugarbud.ca/

Address: Suite 620, 634 – 6th Avenue S.W., Calgary, Alberta T2P 0S4

Forward Looking and Cautionary Statements

This news release contains forward-looking statements. More particularly, and without limitation, this news release contains statements concerning: the Company’s business strategy and future operations, including the Company’s expected business objectives for 2021; ability to identify and successfully execute strategic partnerships; the grant of licenses and regulatory approvals to conduct the Company’s cannabis-related activities; ability to cultivate and produce premium cannabis products; the Company’s cultivation methods; the build out of the Company’s cannabis cultivation and processing facility and lands located in Stavely, Alberta; ability to establish and market the Company’s brand within its targeted markets and compete successfully; ability to produce and market additional products as regulations permit; the distribution and sale of Sugarbud’s cannabis products, including in new markets such as Ontario; future product offerings, including the development, commercialization and sale of Cannabis 2.0 products; legislation, regulations and licensing relating to the cultivation, distribution and sale of cannabis products for recreational and medical purposes; and the Company’s expectations regarding its revenues generated from sales of the Company’s product lines in 2021, including self-sustaining revenue. When used in this document, the words “will,” “anticipate,” “believe,” “estimate,” “expect,” “intent,” “may,” “project,” “should,” and similar expressions are intended to be among the statements that identify forward-looking statements.

The forward-looking statements are founded on the basis of expectations and assumptions made by Sugarbud, including, but not limited to: the success of the Company’s business strategy, including organic growth, acquisitions, partnerships and other strategic activities; ability to manage growth in the Company’s business; the ability to maintain licenses and necessary approvals for Sugarbud to cultivate cannabis at the Stavely facility; ability to cultivate premium cannabis products; ability to sell cannabis products; access to market for the Company’s future cannabis products; impact of increasing competition; ability to keep pace with changing consumer preferences; ability to protect the Company’s intellectual property; timing and amount of capital expenditures; operating costs; government regulations, including future legislative and regulatory developments involving recreational and medical cannabis and the timing thereto; changes to laws regarding the recreational and medical use of cannabis and the impact on the Company’s business strategy; demand for cannabis products and corresponding forecasted increase in revenues; size of the recreational and medical cannabis markets in Canada; legislative and regulatory environments of the jurisdictions where the Company carries on business; ability of the Company to obtain qualified staff, services, supplies and equipment in a timely and cost-efficient manner; the Company’s competitive advantages; conditions in general economic and financial markets;

Forward-looking statements are subject to a wide range of risks and uncertainties, and although Sugarbud believes that the expectations represented by such forward-looking statements are reasonable, there can be no assurance that such expectations will be realized. Any number of important factors could cause actual results to differ materially from those in the forward-looking statements including, but not limited to: the global public health crises in respect of the outbreak of a novel strain of coronavirus (COVID-19), including volatility and disruptions in global supply chains and financial markets, as well as declining trade and market sentiment and reduced mobility of people; success of the operations of the Company; ability of the Company to execute its business strategy; the effect consumer perception of the medical and recreational use of cannabis will have on the market price of cannabis products; the premium segment of the medical and recreational cannabis markets; consumer’s attraction to premium cannabis products and changes in consumer preference; development of the cannabis industry in ways that differ from the Company’s expectations; legislative and regulatory environments of the jurisdictions where the Company carries on business or has operations; ability of Sugarbud to develop or maintain a brand that attracts or retains customers; any failure by the Company to comply with applicable regulations could prevent it from being able to carry on its business, and there may be additional costs associated with any such failure; federal, provincial and municipal government cannabis regulation and changes thereto; actions taken by governmental authorities, including increases in taxes and changes in government regulations; any failure by the Company or its suppliers to comply with supplier standards established by provincial or territorial distributors could prevent the Company from accessing certain markets in Canada; constraints by law in the Company’s ability to market its products in Canada; development of the Stavely facility, including construction delays; availability of sufficient financial resources to fund the Company’s capital expenditures; stock market volatility and market valuations; changes in general economic, market and business conditions; the effect of any future litigation proceedings on the Company’s business; impact of competition and the competitive response to the Company’s business strategy; competition for, among other things, licences, capital, skilled personnel and customers the risks of the cannabis industry, such as regulatory risks and increasing competition; timing and amount of capital and other expenditures; the availability of capital on acceptable terms or at all; cyber-security issues; and, in relation to the Company’s expectations regarding revenues during 2021 and the Company achieving self-sustaining revenue, assumptions relating to production and production capacity, growth in the number of product offerings and store locations in which the Company’s products are sold, growth in total sales, consumer demand for the Company’s products, market pricing of cannabis products, cost of sales, general and administrative expenses (including sales and marketing expenses), the pace of opening of and increase in the total number of recreational cannabis retail stores across Canada, and the total size of the Canadian recreational and medical cannabis markets over that time period. In particular, the Company has assumed and expects that, among other things: (i) its products will meet the specifications of it and its distribution partners, for instance with regard to THC content and other specifications; (ii) the pricing of its products and the product mix of its sales will be consistent with its most recent discussions with its distribution partners; (iii) its Facility will produce between 1,600 kgs and 2,000 kgs in 2021 without additional scale-up, based on the following assumptions: 85 – 100 gram yield per plant; and growing cycle of 10 – 11 weeks per harvest, resulting in 4.75 harvests per year for each room; (iv) the Company will receive an amended sales license from Health Canada prior to the end of Q2 2021, or sell Cannabis 2.0 products pursuant to its existing distribution agreement with a third-party with such license, to permit the Company to sell Cannabis 2.0 products to authorized provincial distributors, retailers and registered medical patients and such products will be developed and move to commercialization by the end of Q3 2021; (v) its cost of sales will be consistent with its current cost of sales throughout 2021; (vi) certain general and administrative expenses are expected to increase if the Company achieves increased sales; and (vii) the total recreational and medical cannabis market in Canada will grow in line with the expectations of the analysts whose reports the Company has reviewed. Please refer to Sugarbud’s most recent annual information form and management’s discussion and analysis for additional risk factors relating to Sugarbud, which can be accessed under Sugarbud’s profile on www.sedar.com. Except as required by applicable laws, Sugarbud does not undertake any obligation to publicly update or revise any forward-looking statements.

This news release contains future-oriented financial information and financial outlook information (collectively, “FOFI”) about the Company’s reasonably estimated prospective results of operations, cannabis production capacity, revenue, expenses, profit and components thereof, all of which are subject to the same assumptions, risk factors, limitations and qualifications as set forth in the above paragraphs, including with respect to economic conditions and proposed courses of action, based on management’s assessment of the relevant information available as of the date of this news release. Sugarbud disclaims any intention or obligation to update or revise any FOFI contained in this news release, whether as a result of new information, future events or otherwise, unless required pursuant to applicable law.


Neither the TSXV nor its regulation services provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.